Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter — ultra-fast Hanzi study All 1,152 characters from the aioLingua manual Abstract • About • The 20 audio files ← aioLingua Chinese Online ← Chinese aioLingua PDF

Gynecology

Free Subscription Articles published in Gynecol Oncol Retrieve available abstracts of 536 articles: HTML format

Single Articles

November 2025
1. TANKOU J, Ruau S, Walia A, Toboni M, et al
   AXL inhibition improves the therapeutic efficacy of trastuzumab in high-risk endometrial cancer.
   Gynecol Oncol. 2025;204:52-62.
   PubMed     Abstract available
   
   
   
2. SHI Y, Gkekos L, Rodriguez-Wallberg KA, Fredriksson I, et al
   Obstetric and perinatal outcomes following a diagnosis of gynecologic cancer during pregnancy.
   Gynecol Oncol. 2025;204:44-51.
   PubMed     Abstract available
   
   
   
3. TOBONI MD, Evans ET, Scalise CB, Hardesty M, et al
   Circulating tumor DNA monitoring in ovarian cancer patients receiving PARPi maintenance therapy: Can we further personalize treatment?
   Gynecol Oncol. 2025;204:37-43.
   PubMed     Abstract available
   
   
   
4. LEE AJ, Jang EB, Suh DH, Chang SJ, et al
   Comparison of oncologic outcomes between completion hysterectomy and no completion hysterectomy in patients who achieved complete response and completed childbearing after fertility-sparing treatment for early-stage endometrial cancer: Gynecologic Onc
   Gynecol Oncol. 2025;203:191-197.
   PubMed     Abstract available
   
   
   
5. BAO W, He X, Huang Y, Xing A, et al
   Effect of uterine manipulator on stage IB1 to IIA1 cervical cancer: A retrospective cohort study.
   Gynecol Oncol. 2025;204:27-36.
   PubMed     Abstract available
   
   
   
6. ARIOLA AB, Nolan B, Johnson L, Cunningham MJ, et al
   The impact of cervical diameter on success of sentinel lymph node mapping in endometrial carcinoma: A retrospective cohort study.
   Gynecol Oncol. 2025;204:23-26.
   PubMed     Abstract available
   
   
   
7. FURUYA RL, Grither W, Evans MG, Wu S, et al
   Comparison of breast and gastric HER2 immunohistochemistry (IHC) scoring criteria in the assessment of endometrial carcinoma.
   Gynecol Oncol. 2025;204:17-22.
   PubMed     Abstract available
   
   
   
8. ARYASOMAYAJULA C, Johnson CR, Francoeur AA, Sia TY, et al
   Pathogenic germline variants among patients with ovarian cancer by self-reported ancestry: A commercial laboratory collaborative research registry study.
   Gynecol Oncol. 2025;204:1-8.
   PubMed     Abstract available
   
   
   
9. CHUNG YE, Kim SI, Noh JJ, Lee JY, et al
   Immune checkpoint inhibitors for recurrent ovarian clear cell carcinoma: Real-world outcomes from a Korean multicenter study.
   Gynecol Oncol. 2025;203:185-190.
   PubMed     Abstract available
   
   
   
10. CORTES-SALGADO A, Moreno-Moreno E, Carretero-Barrio I, Caniego-Casas T, et al
    Corrigendum to 'HER2 expression in a molecularly defined cohort of endometrial cancer patients: The SPECTRUM study' [Gynecologic Oncology 194 (2025) 33-40].
    Gynecol Oncol. 2025;203:184.
    PubMed    
    
    
    
11. THAKER PH, Richardson DL, Hagemann AR, Holloway RW, et al
    Corrigendum to 'OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer' [Gynecol Oncol 2025 Jun 19
    Gynecol Oncol. 2025;203:182-183.
    PubMed    
    
    
    
12. TISCHER KM, Islam NS, McGree ME, Tapia AL, et al
    Quantifying opportunities to reduce high grade serous ovarian cancer via opportunistic salpingectomy.
    Gynecol Oncol. 2025;203:165-170.
    PubMed     Abstract available
    
    
    
13. WASHINGTON C, Dwivedi SKD, Gunderson-Jackson C, Walker J, et al
    Feasibility IB trial of paclitaxel/carboplatin + Galunisertib. (a small molecule inhibitor of the kinase domain of type 1 TGF-B receptor) in patients with newly diagnosed, persistent or recurrent carcinosarcoma of the uterus or ovary.
    Gynecol Oncol. 2025;203:158-164.
    PubMed     Abstract available
    
    
    
14. PARK J, Lee D, Kim S, Kim YN, et al
    Prognostic implications of HER2 in ovarian cancer: Associations with homologous recombination deficiency and folate receptor alpha expression.
    Gynecol Oncol. 2025;203:151-157.
    PubMed     Abstract available
    
    
    
15. BASHI A, Chen L, Rouse K, Elkin EB, et al
    Cost-effectiveness of biomarker-based and universal strategies for the treatment of advanced-stage endometrial cancer.
    Gynecol Oncol. 2025;203:130-138.
    PubMed     Abstract available
    
    
    October 2025
16. MOUFARRIJ S, Friedman CF, Freeman S, Green H, et al
    A pilot study of nivolumab in combination with neoadjuvant and post-surgical chemotherapy in newly diagnosed ovarian cancer.
    Gynecol Oncol. 2025;203:97-104.
    PubMed     Abstract available
    
    
    
17. WHITE VM, Langdale LM, Eroh KD, Ackermann MK, et al
    Experiences of radiotherapy for treatment of Granulosa Cell Tumor of the ovary: insights from the GCT-survivor sisters.
    Gynecol Oncol. 2025;203:112-118.
    PubMed     Abstract available
    
    
    
18. NOZAKI T, Sakamoto I, Kagami K, Matsuda K, et al
    Preoperative molecular classification of endometrial cancer: Validation through biopsy and matched hysterectomy specimens.
    Gynecol Oncol. 2025;203:105-111.
    PubMed     Abstract available
    
    
    
19. LINDGREN A, Benseler A, Hogen L, May T, et al
    Description of first recurrence in advanced stage high grade serous ovarian cancer receiving intraperitoneal versus intravenous systemic treatment.
    Gynecol Oncol. 2025;203:90-96.
    PubMed     Abstract available
    
    
    
20. ARAUJO LW, Maliniak ML, Barber LE, Dilley SE, et al
    Neighborhood socioeconomic status and endometrial cancer mortality: Racial disparities persist across the spectrum.
    Gynecol Oncol. 2025;203:84-89.
    PubMed     Abstract available
    
    
    
21. XU X, Chen L, Nunez-Smith M, Clark M, et al
    Postmenopausal bleeding: Association of initial place of care with stage at diagnosis for uterine cancer.
    Gynecol Oncol. 2025;203:75-83.
    PubMed     Abstract available
    
    
    
22. WANG Y, Li J, Yang Y, Lu X, et al
    Letrozole plus anlotinib as a chemotherapy-free regimen for ER-positive platinum-resistant recurrent epithelial ovarian cancer patients following second-line platinum-based chemotherapy failure: A prospective, single-arm, open-label, phase II study.
    Gynecol Oncol. 2025;203:67-74.
    PubMed     Abstract available
    
    
    
23. SKOLD C, Radestad AF, Bohlin KS, Bjurberg M, et al
    Primary treatment and survival in malignant ovarian germ cell tumors: A nationwide population-based Swedish Gynecologic Cancer Group (SweGCG) study.
    Gynecol Oncol. 2025;203:59-66.
    PubMed     Abstract available
    
    
    
24. TEWARI S, Koelker-Wolfe E, Pelletier A, St Laurent J, et al
    The impact of romiplostim use for chemotherapy induced thrombocytopenia on immediate and long-term outcomes in gynecologic malignancies.
    Gynecol Oncol. 2025;203:53-58.
    PubMed     Abstract available
    
    
    
25. ANDRES S, Tannous A, Kahn RM, Yeoshoua E, et al
    Survival outcomes in patients receiving neoadjuvant chemotherapy for advanced ovarian cancer: Does the indication for neoadjuvant chemotherapy matter?
    Gynecol Oncol. 2025;203:35-42.
    PubMed     Abstract available
    
    
    
26. MANNING B, Banerjee S, Hawkins TB, Winn-Deen ES, et al
    Extracellular vesicle and particle-based blood test for ovarian cancer screening of average risk population: a promising nested case control study using preclinical samples.
    Gynecol Oncol. 2025;203:26-34.
    PubMed     Abstract available
    
    
    
27. MACHIDA H, Kawana K, Okamoto A, Yamagami W, et al
    Impact of neoadjuvant chemotherapy followed by interval debulking surgery on survival in women with advanced non-serous ovarian, fallopian tube, or primary peritoneal cancer.
    Gynecol Oncol. 2025;203:8-15.
    PubMed     Abstract available
    
    
    
28. HOTTON J, Gaillard T, Paoletti X, Raimond E, et al
    Survival impact of residual disease and timing of surgery in the management of advanced-stage low grade serous ovarian cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2025;203:16-25.
    PubMed     Abstract available
    
    
    
29. MAURER T, Belau MH, Zyriax BC, Welsch G, et al
    Development and optimization of an integrated exercise and nutrition program for ovarian cancer patients: Phase I of the BENITA multi-center study.
    Gynecol Oncol. 2025;202:167-173.
    PubMed     Abstract available
    
    
    
30. HOLTZMAN S, Myers E, Havrilesky LJ, Yamada D, et al
    Gynecologic oncology fellowship trends: Supply outpacing demand, geographical maldistribution.
    Gynecol Oncol. 2025;202:162-166.
    PubMed     Abstract available
    
    
    
31. DAGHER C, Selenica P, Bakhuis CFJ, Green H, et al
    Prognostic value of positive peritoneal cytology in FIGO 2009 stage IA grade 1 endometrioid endometrial cancer.
    Gynecol Oncol. 2025;202:154-161.
    PubMed     Abstract available
    
    
    
32. KIM U, Oh BC, Bae J, Kang S, et al
    Survival outcomes and treatment patterns in malignant ovarian sex cord-stromal tumors: A population-based analysis.
    Gynecol Oncol. 2025;202:146-153.
    PubMed     Abstract available
    
    
    
33. POWELL CA, Winer IS, Tarney CM, Gaillard S, et al
    Interstitial lung disease in targeted therapies: A Society of Gynecologic Oncology clinical practice statement.
    Gynecol Oncol. 2025;202:137-145.
    PubMed     Abstract available
    
    
    
34. ETTORRE VM, Bellone S, Buza N, Hui P, et al
    Immunohistochemistry, next generation sequencing (NGS), and whole exome sequencing concordance in HER2 testing in uterine serous carcinoma: a retrospective analysis.
    Gynecol Oncol. 2025;202:131-136.
    PubMed     Abstract available
    
    
    
35. BORDEN BA, Rodriguez-Hernandez A, Trottier M, Horiguchi M, et al
    SMARCA4 pathogenic variants: Gynecological cancer histories from a laboratory tested cohort.
    Gynecol Oncol. 2025;202:125-130.
    PubMed     Abstract available
    
    
    
36. KOCIAN R, Kohler C, Klat J, Jarkovsky J, et al
    Sentinel lymph node mapping in early-stage cervical cancer: Results from the SENTIX prospective multicenter study.
    Gynecol Oncol. 2025;202:118-124.
    PubMed     Abstract available
    
    
    
37. GARG V, Armstrong E, Celeste A, Wang C, et al
    Multidisciplinary ambulatory management of malignant bowel obstruction (MAMBO) program in patients with advanced gynecological cancers: A prospective study.
    Gynecol Oncol. 2025;202:110-117.
    PubMed     Abstract available
    
    
    
38. LIM JW, Dzyubak O, Moshkovich M, Maganti M, et al
    Impact of FIGO 2023 staging criteria on stage migration and survival outcomes in early-stage endometrial cancer: A retrospective cohort study.
    Gynecol Oncol. 2025;202:93-101.
    PubMed     Abstract available
    
    
    
39. CHASE DM, Huang HQ, Deng W, Koh WJ, et al
    Patient-reported outcomes of a randomized phase III clinical trial of adjuvant radiation versus chemoradiation in intermediate risk, stage I/IIA cervical cancer patients treated with initial radical hysterectomy and pelvic lymphadenectomy (NRG/GOG-026
    Gynecol Oncol. 2025;202:102-109.
    PubMed     Abstract available
    
    
    
40. NEPHEW KP, Drapkin R, Lang J, Zhuravlev Y, et al
    The 15th Biennial Rivkin Center ovarian cancer research symposium.
    Gynecol Oncol. 2025;201:A1-A2.
    PubMed     Abstract available
    
    
    
41. KHADRAOUI W, Felix AS, Meade CE, Chalif J, et al
    Prognostic and demographic patterns in serous tubal intraepithelial carcinoma: A National Cancer Database study.
    Gynecol Oncol. 2025;201:76-82.
    PubMed     Abstract available
    
    
    
42. BLANK SV, Frey MK
    Does a diagnosis of breast cancer reduce ovarian cancer risk in BRCA1/2 3 carriers: Why is this a question?
    Gynecol Oncol. 2025;201:A3-A4.
    PubMed    
    
    
    September 2025
43. JANKE MJ, Minns A, Pesce MM, McLaughlin HD, et al
    Trends in pre-fellowship research productivity among matched gynecologic oncology fellows.
    Gynecol Oncol. 2025;202:87-92.
    PubMed     Abstract available
    
    
    
44. GERSHENSON DM, Burns K, Sun C
    Update on contemporary treatment for newly diagnosed stage II-IV low-grade serous ovarian/peritoneal cancer (LGSOC).
    Gynecol Oncol. 2025;202:85-86.
    PubMed    
    
    
    
45. SIA TY, Brown DN, Miller K, Curtin C, et al
    Uterine leiomyosarcoma progression: A study of serial recurrences.
    Gynecol Oncol. 2025;202:77-84.
    PubMed     Abstract available
    
    
    
46. SOMASEGAR S, Zhang J, Fotopoulou C, Fumagalli D, et al
    The role of neoadjuvant chemotherapy in advanced-stage clear cell ovarian cancer: A GCIG multi-institutional retrospective cohort study.
    Gynecol Oncol. 2025;202:59-65.
    PubMed     Abstract available
    
    
    
47. GENG F, Wang Y, Cui G, Fan M, et al
    TRIB3 promotes endometrial cancer progression through interacting with E2F1 and enhancing PKM2-mediated tumor glycolysis.
    Gynecol Oncol. 2025;202:41-52.
    PubMed     Abstract available
    
    
    
48. AN J, Li G, Zhang Y, Feng M, et al
    Sacituzumab govitecan in Chinese patients with recurrent/metastatic cervical cancer: Results from the phase 2 EVER-132-003 basket study (NCT05119907).
    Gynecol Oncol. 2025;202:33-40.
    PubMed     Abstract available
    
    
    
49. SUGIYAMA Y, Kosugi M, Gotoh O, Tonooka A, et al
    Genomic and DNA methylomic factors associated with the efficacy of oral medroxyprogesterone acetate on endometrial neoplastic disease.
    Gynecol Oncol. 2025;202:24-32.
    PubMed     Abstract available
    
    
    
50. YOH K, Desai VB, Gross CP, Spatz ES, et al
    Physician variation in adopting opportunistic salpingectomy at the time of postpartum and interval sterilization for ovarian cancer risk reduction.
    Gynecol Oncol. 2025;202:1-13.
    PubMed     Abstract available
    
    
    
51. LOUKOVAARA M, Pasanen A, Butzow R
    Distinct clinical outcomes according to molecular subgroups in relapsed endometrial carcinoma: A cohort study.
    Gynecol Oncol. 2025;201:216-222.
    PubMed     Abstract available
    
    
    
52. ACKROYD SA, Sudilovsky G, Che Y, Wesevich A, et al
    Race and neighborhood disadvantage in patients with stage I-III endometrioid endometrial carcinoma treated at a tertiary referral center.
    Gynecol Oncol. 2025;201:203-209.
    PubMed     Abstract available
    
    
    
53. FULGIONE C, Inzani F, Raffone A, Raimondo D, et al
    Prognosis of HPV-independent, p53-wild-type vulvar squamous cell carcinoma: A systematic review and meta-analysis.
    Gynecol Oncol. 2025;201:210-215.
    PubMed     Abstract available
    
    
    
54. ETTORRE VM, Demirkiran C, Bellone S, Hartwich TMP, et al
    Effective preclinical activity of datopotamab deruxtecan (Dato-DXd), an ADC targeting trophoblast cell-surface antigen 2 (TROP2), against primary cervical carcinoma cell lines and xenografts.
    Gynecol Oncol. 2025;201:195-202.
    PubMed     Abstract available
    
    
    
55. MATSUO K, Enserro DM, Wright JD, Roman LD, et al
    Prospective assessment of prognostic significance of malignant peritoneal cytology in endometrial cancer: An NRG Oncology / Gynecologic Oncology Group study on GOG-210 protocol.
    Gynecol Oncol. 2025;201:184-194.
    PubMed     Abstract available
    
    
    
56. LIN Z, Liu Z, Chen J, Gu H, et al
    Novel anatomical concept and standardized technique for single-port Paraaortic lymphadenectomy in gynecological cancers.
    Gynecol Oncol. 2025;201:176-183.
    PubMed     Abstract available
    
    
    
57. REBOUILLAT C, Pomel C, Bourdel N, Mimoun C, et al
    Diagnostic laparoscopy and cytoreduction surgery in ovarian cancer FIGO III-IV: The impact on survival of one-stage versus two-stage sequence.
    Gynecol Oncol. 2025;201:167-175.
    PubMed     Abstract available
    
    
    
58. CHIAPPINELLI KB, Christie EL, Padmanabhan A
    Biology of ovarian cancer: Models, microenvironment, and therapeutics: 15th Biennial Rivkin Center Ovarian Cancer Research Symposium.
    Gynecol Oncol. 2025;201:160-163.
    PubMed     Abstract available
    
    
    
59. ZHOU N, Beavis AL, Lin LL, Neibart SS, et al
    Embracing and implementing the WHO cervical cancer elimination campaign goals: A consensus statement by SGO, ACOG, ASCCP, ASTRO, and ABS on minimum quality care standards for cervical cancer patients in the U.S.
    Gynecol Oncol. 2025;200:193-202.
    PubMed     Abstract available
    
    
    
60. NEIBART S, Zhou N, Chino J, Earles T, et al
    Health equity, disparities, and barriers to cervical cancer care in the U.S.: A consensus statement by SGO, ACOG, ASCCP, ASTRO, and ABS addressing the WHO cervical Cancer elimination campaign goals related to treatment.
    Gynecol Oncol. 2025;200:186-192.
    PubMed     Abstract available
    
    
    
61. NEIBART SS, Lin LL, Einstein MH, Teoh D, et al
    Minimum standards for radiation therapy in the treatment of cervical cancer in the U.S.: A consensus statement by SGO, ASTRO, and ABS addressing the WHO Cervical Cancer Elimination Campaign goals.
    Gynecol Oncol. 2025;200:180-185.
    PubMed     Abstract available
    
    
    
62. MATSUBARA M, Otani T, Kawakami F, Koike A, et al
    Cervical adenocarcinoma risk stratification using histotype and invasion pattern: a multicenter retrospective study by the KAMOGAWA Study Group.
    Gynecol Oncol. 2025;200:112-121.
    PubMed     Abstract available
    
    
    
63. SCHAAFSMA M, Schuurman TN, Bekkers RLM, Dunne FR, et al
    The risk for residual AIS/CIN3+ after the first conservative surgical procedure for cervical adenocarcinoma in situ - A Dutch retrospective cohort study.
    Gynecol Oncol. 2025;200:44-50.
    PubMed     Abstract available
    
    
    
64. JAEGER A, Hampl M, Prieske K, Eulenburg C, et al
    Risk for non-sentinel metastases in the contralateral groin in patients with a unilateral positive sentinel lymph node in primary vulvar cancer- a subgroup analysis of the AGO-VOP.2 QS Vulva Study.
    Gynecol Oncol. 2025;200:8-13.
    PubMed     Abstract available
    
    
    
65. MULLEN MM, Arend RC
    From one-size-fits all to biology-driven care: Emerging paradigms in gynecologic oncology.
    Gynecol Oncol. 2025;200:A1-A2.
    PubMed    
    
    
    August 2025
66. BRODSKY AL, Welte T, Vuttaradhi VK, Yang X, et al
    Efficacy of cyclin-dependent kinase 4/6 inhibitors in preclinical adult-type ovarian granulosa cell tumor models.
    Gynecol Oncol. 2025;201:152-159.
    PubMed     Abstract available
    
    
    
67. MORTON M, Chalif J, Sciuva J, Fulton J, et al
    The price of delay: Insurance-related treatment delays in patients with gynecologic cancer receiving immunotherapy.
    Gynecol Oncol. 2025;201:144-151.
    PubMed     Abstract available
    
    
    
68. BRUCE KH, Xu C, Shah RP, McGree ME, et al
    Real-world outcomes of neoadjuvant chemotherapy for advanced ovarian cancer: What happens to patients who never undergo surgery?
    Gynecol Oncol. 2025;201:137-143.
    PubMed     Abstract available
    
    
    
69. ANDRES S, Brown DN, Da Cruz Paula A, Aghajanian C, et al
    Whole-genome sequencing-based characterization of endometrial serous carcinoma.
    Gynecol Oncol. 2025;201:130-136.
    PubMed     Abstract available
    
    
    
70. CHERRY DR, Gupta V, Bloom JR, Hsieh K, et al
    Early-stage uterine papillary serous carcinoma: Clinical outcomes in patients treated with adjuvant chemotherapy and vaginal brachytherapy.
    Gynecol Oncol. 2025;201:123-129.
    PubMed     Abstract available
    
    
    
71. SMITH AJ, Acharya R, Ang L, Moore T, et al
    "What you're hearing from all of us is simplify the language": Patient perspectives on biomarker testing in ovarian cancer.
    Gynecol Oncol. 2025;201:118-122.
    PubMed     Abstract available
    
    
    
72. SOONG TR, Islam BN, Hunt K, Nadeem A, et al
    Research is care: How patients and researchers can work together to bring the bedside back to the bench - a patient advocacy panel discussion: 15th Biennial Rivkin Center Ovarian Cancer Research Symposium.
    Gynecol Oncol. 2025;201:114-117.
    PubMed     Abstract available
    
    
    
73. PERELMUTER S, Leung AC, Ahsan MD, Webster EM, et al
    Virtual versus reality: Assessing the accuracy of a digital cancer risk assessment tool in a gynecologic oncology clinic.
    Gynecol Oncol. 2025;200:169-174.
    PubMed     Abstract available
    
    
    
74. LANITI DD, Verma P
    State-of-the art in emerging therapeutics for ovarian cancer therapy.
    Gynecol Oncol. 2025;201:109-113.
    PubMed     Abstract available
    
    
    
75. ZHANG N, Porter RL
    Emerging approaches to enhance immune responses in ovarian cancer: 15th biennial Rivkin Center Ovarian Cancer Research Symposium.
    Gynecol Oncol. 2025;201:97-101.
    PubMed     Abstract available
    
    
    
76. GAILLARD S, Alvarez J, Zhang T, Wang H, et al
    A randomized pilot study of HPV16 L2E7E6 fusion protein vaccination site post-treatment for HPV16+ cervical cancer.
    Gynecol Oncol. 2025;201:86-96.
    PubMed     Abstract available
    
    
    
77. SOZEN H, Minareci Y, Toyran A, Tutar E, et al
    Evaluation of total retroperitoneal en-bloc resection of multivisceral-peritoneal packet (TROMP) in advanced ovarian cancer: A single-center cohort study.
    Gynecol Oncol. 2025;201:102-108.
    PubMed     Abstract available
    
    
    
78. ROBIN TP, Hu J, Jones BL, Patton T, et al
    Phase I trial of stereotactic body radiation therapy (SBRT) for limited site locoregional recurrences of ovarian cancer.
    Gynecol Oncol. 2025;200:175-179.
    PubMed     Abstract available
    
    
    
79. GASPAR-MAIA A, Sasamoto N
    Prevention, early detection & interception: 15th biennial ovarian cancer research symposium.
    Gynecol Oncol. 2025;201:83-85.
    PubMed     Abstract available
    
    
    
80. CORR BR, Thomas SM, Haight PJ, Stock E, et al
    Evaluation of the combination lenvatinib and pembrolizumab in endometrial cancer; a real world multi-institutional review of practice patterns, efficacy and tolerability.
    Gynecol Oncol. 2025;201:69-75.
    PubMed     Abstract available
    
    
    
81. SIA TY, Moufarrij S, Milani J, Kane S, et al
    Germline landscape of high grade serous ovarian cancer across age groups: Is age just a number?
    Gynecol Oncol. 2025;201:60-68.
    PubMed     Abstract available
    
    
    
82. BRUBAKER LW, Merritt MA
    Ovarian cancer health disparities: 15th Biennial Rivkin Center Ovarian Cancer Research Symposium.
    Gynecol Oncol. 2025;201:56-59.
    PubMed     Abstract available
    
    
    
83. FITCH KC, Previs RA, Moss HA
    The promise and perils of biomarker testing in gynecologic cancers.
    Gynecol Oncol. 2025;201:53-55.
    PubMed    
    
    
    
84. APOSTOL AI, Kotsopoulos J, Gronwald J, Kim RH, et al
    Ovarian cancer after breast cancer in women with a BRCA1 or BRCA2 pathogenic variant.
    Gynecol Oncol. 2025;201:44-52.
    PubMed     Abstract available
    
    
    
85. NG ZY, McCluggage WG, Dundr P, Borcinova M, et al
    Evaluation of the significance of isolated tumor cells in gynecological cancers.
    Gynecol Oncol. 2025;201:40-43.
    PubMed     Abstract available
    
    
    
86. POLEN-DE CL, Giannini A, Langstraat CL, Moreno AG, et al
    Effect of conization, manipulator use, and their interaction on recurrence after radical hysterectomy for cervical cancer: A multicenter retrospective analysis.
    Gynecol Oncol. 2025;201:33-39.
    PubMed     Abstract available
    
    
    
87. TOWNER M, Grace A, Marcus J
    Beating cancer while building families: A mixed methods study on parenting, life choices, and career trajectories of gynecologic oncologists in the United States.
    Gynecol Oncol. 2025;201:26-32.
    PubMed     Abstract available
    
    
    
88. CHATOR C, Chevrier M, Frenel JS, Guyon F, et al
    Role of platinum-free interval (PFI) and maintenance therapies in recurrent ovarian cancer to explain survival. An analysis from the French real-world ESME Ovarian Database.
    Gynecol Oncol. 2025;201:17-25.
    PubMed     Abstract available
    
    
    
89. SPENARD E, Lin Y, Covens A, Gien LT, et al
    Optimizing the screening and management of preoperative anemia prior to gynecologic oncology surgery (OPRA1): A quality improvement initiative.
    Gynecol Oncol. 2025;201:7-16.
    PubMed     Abstract available
    
    
    
90. HACKER KE, A Fleming K, Gupta M, Pothuri B, et al
    HER2 expression in an endometrial cancer cohort.
    Gynecol Oncol. 2025;201:1-6.
    PubMed     Abstract available
    
    
    
91. BOGANI G, Fagotti A, Chiantera V, De Iaco P, et al
    The role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer.
    Gynecol Oncol. 2025;200:161-168.
    PubMed     Abstract available
    
    
    
92. WANG Y, Jia Z, Jiao J, Yue X, et al
    Analysis of the use of prophylactic ureteral stents in preventing iatrogenic ureteral injury during radical hysterectomy for cervical Cancer.
    Gynecol Oncol. 2025;200:155-160.
    PubMed     Abstract available
    
    
    
93. MARCHETTI M, Vezzaro T, Carollo M, Facchetti E, et al
    The challenge of molecular stratification in No Specific Molecular Profile endometrial cancer.
    Gynecol Oncol. 2025;200:145-154.
    PubMed     Abstract available
    
    
    
94. CLARKE MA, Wentzensen N, Kobel M, Erickson BK, et al
    Age-specific incidence and five-year relative survival of endometrial cancer histotypes by race and ethnicity among US women, 2000 to 2019.
    Gynecol Oncol. 2025;200:137-144.
    PubMed     Abstract available
    
    
    
95. RISHI A, Albuquerque KV, Jhingran A, Donovan EK, et al
    Definitive intensity-modulated radiotherapy for organ preservation in vulvar cancer: A multicenter study.
    Gynecol Oncol. 2025;199:1-9.
    PubMed     Abstract available
    
    
    July 2025
96. BRODSKY AL, Sun C, Cobb L, Westin SN, et al
    Ovarian mixed low- and high-grade serous carcinoma as a synchronous or metachronous phenomenon: A clinicopathologic study of 39 cases.
    Gynecol Oncol. 2025;200:130-136.
    PubMed     Abstract available
    
    
    
97. WANG JY, Simons EJ, Dingel A, Pike MM, et al
    Impact of chemotherapy provider specialty on outcomes in ovarian cancer.
    Gynecol Oncol. 2025;200:122-129.
    PubMed     Abstract available
    
    
    
98. LIGHTFOOT MDS, Sinnott JA, Meade CE, Barrington DA, et al
    Enhancing predictive accuracy: Assessing the laparoscopic hysterectomy readmission score in a diverse endometrial cancer population.
    Gynecol Oncol. 2025;200:105-111.
    PubMed     Abstract available
    
    
    
99. LEE KJ, Chokshi S, Joshi T, Cummings M, et al
    Molecular comparison reveals distinct transcriptomic differences between uterine carcinosarcoma and papillary serous carcinoma distinguishable by DNA damage.
    Gynecol Oncol. 2025;200:80-87.
    PubMed     Abstract available
    
    
    
100. MATULONIS UA, Vergote I, Moore KN, Martin LP, et al
     Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRalpha)-targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancer.
     Gynecol Oncol. 2025;200:96-104.
     PubMed     Abstract available
     
     
     
101. RAGLAND K, Pogue J, Simiele E, Simiele S, et al
     The use of transrectal ultrasound to improve gynecologic interstitial applicator implantation.
     Gynecol Oncol. 2025;200:88-95.
     PubMed     Abstract available
     
     
     
102. MCGAURAN M, Hyde S, Perera S, Lloyd M, et al
     Perioperative outcomes after interval cytoreductive surgery and primary cytoreductive surgery for advanced epithelial ovarian cancer in Australia: A National Gynae-Oncology Registry (NGOR) study.
     Gynecol Oncol. 2025;200:72-79.
     PubMed     Abstract available
     
     
     
103. CORR BR, Haggerty A, Gysler SM, Taylor S, et al
     A phase II, randomized, double-blind study of the use of rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer.
     Gynecol Oncol. 2025;200:58-67.
     PubMed     Abstract available
     
     
     
104. PESCE M, Tondo-Steele K, Stroup C, Straubhar A, et al
     Persistent opioid use among gynecologic oncology patients after surgery.
     Gynecol Oncol. 2025;200:68-71.
     PubMed     Abstract available
     
     
     
105. LAVEN P, Wenzel HHB, van der Aa MA, Lambrechts S, et al
     Impact of lymph node dissection and adjuvant chemotherapy on survival of patients with early-stage ovarian cancer: Update of a national cohort study.
     Gynecol Oncol. 2025;200:51-57.
     PubMed     Abstract available
     
     
     
106. CARUSO G, Ainio C, Fumagalli D, Reynolds EA, et al
     Textbook oncologic outcome in endometrial cancer surgery: A quality measure to improve survival and address disparities.
     Gynecol Oncol. 2025;200:33-43.
     PubMed     Abstract available
     
     
     
107. HE SY, Shen HW, Xu L, Zhao XH, et al
     Corrigendum to "FOXM1 promotes tumor cell invasion and correlates with poor prognosis in early-stage cervical cancer" [Gynecologic Oncology 127 (2012) 601-610].
     Gynecol Oncol. 2025 Jul 17:S0090-8258(25)00897.
     PubMed    
     
     
     
108. STOVER EH, Lee EK, Shapiro GI, Brugge JS, et al
     The RAS-MEK-ERK pathway in low-grade serous ovarian cancer.
     Gynecol Oncol. 2025;200:22-32.
     PubMed     Abstract available
     
     
     
109. KOIKE Y, Fujiwara A, Seki T, Kochi Y, et al
     The detrimental impact of diverting ileostomy on renal function after tumor debulking surgery for advanced ovarian cancer.
     Gynecol Oncol. 2025;200:14-21.
     PubMed     Abstract available
     
     
     
110. HUBINETTE M, Sundstrom-Poromaa I, Persson S, Elenis E, et al
     Polycystic ovary syndrome and the risk of ovarian tumours.
     Gynecol Oncol. 2025;200:1-7.
     PubMed     Abstract available
     
     
     
111. LEE SS, Secord AA, Friedman S, Hade EM, et al
     Molecular characteristics by race and ethnicity of patients with high tumor mutational burden, high microsatellite instability, and mismatch repair deficiency: Real-world data from the multi-institutional Endometrial cancer Molecularly Targeted Therap
     Gynecol Oncol. 2025;199:152-158.
     PubMed     Abstract available
     
     
     
112. BEKTAS O, Bektas K
     Prognostic value of systemic inflammatory markers in predicting neoadjuvant platinum response and platinum resistance in advanced epithelial ovarian cancer: A peritoneal cancer index-based analysis.
     Gynecol Oncol. 2025;199:147-151.
     PubMed     Abstract available
     
     
     
113. RODRIGUEZ VE, Ro A, Hoyt MA, Tanjasiri SP, et al
     Racial/ethnic disparities in time from diagnosis to surgical treatment for type I and type II endometrial carcinomas.
     Gynecol Oncol. 2025;199:139-146.
     PubMed     Abstract available
     
     
     
114. AINIO C, Rosanu M, Ribero L, Caruso G, et al
     Surgical complexity and scope of procedures necessary after neoadjuvant chemotherapy for primary ovarian cancer.
     Gynecol Oncol. 2025;199:133-138.
     PubMed     Abstract available
     
     
     
115. SU H, Shang X, Liu H, Tian M, et al
     Low-dose lenvatinib plus toripalimab for patients with platinum-resistant recurrent ovarian cancer: preliminary results from a multicenter, phase II trial (NCT06241105).
     Gynecol Oncol. 2025;199:124-132.
     PubMed     Abstract available
     
     
     
116. SILBERMAN JN, Benjamin A, Solk P, Matei D, et al
     Fit4Surgery: A pilot randomized controlled trial to assess the feasibility of prehabilitation prior to debulking surgery for ovarian cancer.
     Gynecol Oncol. 2025;199:116-123.
     PubMed     Abstract available
     
     
     
117. LIANG MI, Aviki EM, Agarwal R, Dholakia J, et al
     What are we worth? An SGO analysis of compensation structures that measure and value work in academic gynecologic oncology practices.
     Gynecol Oncol. 2025;199:108-115.
     PubMed     Abstract available
     
     
     
118. JOHNSON B, Milicia A, Hicks J, Hoskins E, et al
     Delays, fragmentation, and desire for alternatives: A qualitative study of the patient experience through diagnosis and treatment of endometrial cancer.
     Gynecol Oncol. 2025;199:103-107.
     PubMed     Abstract available
     
     
     
119. HARDESTY MM, Krivak TC, Wright GS, Hamilton E, et al
     A phase 2 trial of niraparib plus bevacizumab maintenance therapy following first-line platinum-based chemotherapy with bevacizumab in advanced ovarian cancer: final analysis and overall survival results from OVARIO.
     Gynecol Oncol. 2025;199:96-102.
     PubMed     Abstract available
     
     
     June 2025
120. RANDALL L, Xiang Y, Matsumoto T, Giannarelli D, et al
     Patient-reported outcomes from the phase 3, randomized, double-blind, placebo-controlled ENGOT-cx11/GOG-3047/KEYNOTE-A18 study of pembrolizumab plus concurrent chemoradiotherapy in participants with high-risk locally advanced cervical cancer.
     Gynecol Oncol. 2025;199:88-95.
     PubMed     Abstract available
     
     
     
121. LINDEMANN K, Berton D, Sehouli J, Christensen RD, et al
     NSGO-FANDANGO/ENGOT-EN1: A randomized phase II study of first-line combination chemotherapy with nintedanib/placebo in advanced/recurrent endometrial cancer.
     Gynecol Oncol. 2025;199:79-87.
     PubMed     Abstract available
     
     
     
122. DZYUBAK O, Glass K, Watts M, Tarafdar O, et al
     Oncologic and fertility outcomes of progestin therapy for atypical hyperplasia and grade 1 cancer of the endometrium: Results of a specialized oncofertility program.
     Gynecol Oncol. 2025;199:72-78.
     PubMed     Abstract available
     
     
     
123. GREENMAN M, Bellone S, Demirkiran C, Hartwich TMP, et al
     Datopotamab deruxtecan, a novel TROP2-tareting antibody-drug conjugate with a topoisomerase I inhibitor payload, shows preclinical activity against primary and metastatic uterine and ovarian TROP2 over-expressing carcinosarcoma.
     Gynecol Oncol. 2025;199:64-71.
     PubMed     Abstract available
     
     
     
124. WANG M, Dong T, Lucero M, Pan W, et al
     Association between glucagon-like peptide-1 receptor agonists and ovarian cancer survival: A population-based cohort study.
     Gynecol Oncol. 2025;199:57-63.
     PubMed     Abstract available
     
     
     
125. CHAN JK, Tewari K, Monk BJ, Herzog TJ, et al
     Optimizing therapy for cervical cancers - Translating trial data into clinical decision-making.
     Gynecol Oncol. 2025;199:47-50.
     PubMed    
     
     
     
126. KAHVECIOGLU A, Gultekin M, Yigit E, Sari SY, et al
     Adjuvant radiotherapy outcomes and prognostic factors in FIGO 2023 stage IIC endometrial cancer: One sea, different depths.
     Gynecol Oncol. 2025;199:40-46.
     PubMed     Abstract available
     
     
     
127. VARGIU V, Rosati A, Santullo F, Figa M, et al
     REACT bowel REcovery after CyToreductive surgery for advanced ovarian cancer.
     Gynecol Oncol. 2025;199:32-39.
     PubMed     Abstract available
     
     
     
128. LIU Y, Zhou Y, Zhou Z, Rao X, et al
     GTN misdiagnosed as ectopic pregnancy: a 17-year retrospective cohort study.
     Gynecol Oncol. 2025;199:27-31.
     PubMed     Abstract available
     
     
     
129. WEI TY, Wu CC, Hsu YT, Lin WH, et al
     An exploratory analysis of driver gene alterations and their potential prognostic relevance in endometrial cancer with POLE exonuclease domain mutations.
     Gynecol Oncol. 2025;199:17-26.
     PubMed     Abstract available
     
     
     
130. BIANCHI T, Grassi T, De Ponti E, Jaconi M, et al
     Fertility sparing surgery in patients with advanced borderline ovarian tumors: Oncologic outcomes of a single-institution cohort.
     Gynecol Oncol. 2025;199:10-16.
     PubMed     Abstract available
     
     
     
131. HUEPENBECKER SP, Iniesta MD, Munsell MF, Mandayam S, et al
     No increase in chronic kidney disease after postoperative acute kidney injury in gynecologic oncologic ERAS surgery.
     Gynecol Oncol. 2025;198:168-175.
     PubMed     Abstract available
     
     
     
132. DAMIAN FB, De Melo AC, Dal Molin GZ, Nogueira-Rodrigues A, et al
     A phase II trial of palbociclib plus letrozole after progression on second-line chemotherapy for women with hormone receptor-positive high-grade serous or endometrioid ovarian, fallopian tube, or peritoneal cancer (LACOG 1018).
     Gynecol Oncol. 2025;198:161-167.
     PubMed     Abstract available
     
     
     
133. VINTZILEOS W, Beer H, Sunkara Y, Pruszynski J, et al
     Prognostic indicators of recurrence and treatment-free interval in uterine carcinosarcoma.
     Gynecol Oncol. 2025;198:154-160.
     PubMed     Abstract available
     
     
     
134. BOUAZZI M, Zheng G, Wang J, Baandrup L, et al
     Use of statins and risk of ovarian cancer: evidence on effect modification by parity, menopause and endometriosis from nationwide nested case-control studies.
     Gynecol Oncol. 2025;198:130-136.
     PubMed     Abstract available
     
     
     
135. MATSUO K, Friedman EL, Lee MW, Masjedi AD, et al
     Cytology-negative, non-myoinvasive stage IC serous endometrial cancer: Assessment of adjuvant chemotherapy omission.
     Gynecol Oncol. 2025;198:146-153.
     PubMed     Abstract available
     
     
     
136. NGUYEN JMV, Zigras T, Gayowsky A, Marcucci M, et al
     Association of frailty with perioperative and survival outcomes in patients with gynecologic cancers: A population-based study.
     Gynecol Oncol. 2025;198:137-145.
     PubMed     Abstract available
     
     
     
137. FU Z, Borho L, Taylor SE, Kelemen LE, et al
     Ovarian cancer risk and survival according to tumor sex hormone receptor expression: An ovarian Cancer association consortium and ovarian tumor tissue analysis consortium pooled analysis.
     Gynecol Oncol. 2025;198:112-129.
     PubMed     Abstract available
     
     
     
138. MELO V, Vanegas G, O'Riordan DL, Kuruvilla P, et al
     A population health approach to assessing for and addressing palliative care needs in outpatients with advanced gynecologic malignancies.
     Gynecol Oncol. 2025;198:104-111.
     PubMed     Abstract available
     
     
     
139. INIESTA MD, Ramirez PT, Munsell MF, Basabe S, et al
     Integration of self-hypnosis in an enhanced recovery after surgery program in gynecologic oncology - A prospective randomized trial.
     Gynecol Oncol. 2025;198:96-103.
     PubMed     Abstract available
     
     
     
140. RING KL, Mills AM, Howitt BE, Grisham RN, et al
     Mesonephric-like adenocarcinoma of the female genital tract: Pathologic diagnosis, clinical outcomes, and novel therapeutics.
     Gynecol Oncol. 2025;197:57-65.
     PubMed     Abstract available
     
     
     
141. KURNIT KC
     The search for new therapeutic options for uterine carcinosarcoma.
     Gynecol Oncol. 2025;197:A1-A2.
     PubMed    
     
     
     May 2025
142. KISTENFEGER Q, Haight PJ, Levine M, Wang H, et al
     The impact of antibiotics, proton pump inhibitors, H2-receptor antagonists, and steroids on survival in ovarian cancer patients receiving PARP inhibitor therapy.
     Gynecol Oncol. 2025;198:90-95.
     PubMed     Abstract available
     
     
     
143. CHO WK, Park W, Kim SW, Lee KK, et al
     Postoperative hypofractionated intensity-modulated radiation therapy in cervical cancer: prospective phase 2 trial (POHIM_RT study).
     Gynecol Oncol. 2025;198:84-89.
     PubMed     Abstract available
     
     
     
144. PHAM ENB, van den Berg CB, Kokke NCCJ, van Marion R, et al
     Molecular diversity in uterine carcinosarcoma: Beyond TP53.
     Gynecol Oncol. 2025;198:75-83.
     PubMed     Abstract available
     
     
     
145. IIDA Y, Churchman M, Hollis RL, Taylor S, et al
     Combined genomic and molecular analysis defines prognostic markers of relapse in stage IA-IC1 clear cell ovarian carcinoma.
     Gynecol Oncol. 2025;198:66-74.
     PubMed     Abstract available
     
     
     
146. LAM C, Zhou Q, Aghajanian C, Abu-Rustum NR, et al
     Prognostic significance of estrogen receptor expression and estrogen signaling in endometrial carcinomas of no specific molecular profile: A comprehensive molecular and pathologic analysis.
     Gynecol Oncol. 2025;198:59-65.
     PubMed     Abstract available
     
     
     
147. EHIMIAGHE E, Marjon N, Post MD, Corr BR, et al
     The evolving role of HER2 in gynecologic oncology and clinical trial design: A gynecologic pathologist's perspective.
     Gynecol Oncol. 2025;198:55-58.
     PubMed    
     
     
     
148. ACOSTA U, Bebia V, Torne A, Carreras-Dieguez N, et al
     Topographic mapping of pelvic and aortic lymph node metastases in stage IIIC1r locally advanced cervical cancer: A retrospective study by the Spain-GOG group.
     Gynecol Oncol. 2025;198:49-54.
     PubMed     Abstract available
     
     
     
149. NEWELL A, Andac-Jones E, Gonzalo M, Wright AA, et al
     Patients with advanced ovarian cancer and their experiences and perceptions of sleep disturbance and fatigue across the treatment trajectory: A qualitative study.
     Gynecol Oncol. 2025;198:42-48.
     PubMed     Abstract available
     
     
     
150. YANG W, Shen Y, Tian Y, Xiao X, et al
     Evaluation of mutations detected in uterine exfoliated cells as a diagnostic tool for endometrial cancer.
     Gynecol Oncol. 2025;198:33-41.
     PubMed     Abstract available
     
     
     
151. LEE JY, Boonyapipat S, Yuan G, Kim HS, et al
     AdvanTIG-202: Phase 2 open-label, two-cohort multicenter study of ociperlimab plus tislelizumab and tislelizumab alone in patients with previously treated recurrent or metastatic cervical cancer.
     Gynecol Oncol. 2025;198:25-32.
     PubMed     Abstract available
     
     
     
152. GU J, Zheng W, Li F, Luo C, et al
     Redefining stage IVB cervical cancer: The unique prognosis of distant lymph node metastasis which is comparable to stage IIIC.
     Gynecol Oncol. 2025;198:17-24.
     PubMed     Abstract available
     
     
     
153. BERG HF, Trovik J, Hjelmeland ME, Lien HE, et al
     Pragmatic preoperative molecular classification of endometrial cancers; Replacing POLE sequencing with hormone receptor staining.
     Gynecol Oncol. 2025;198:9-16.
     PubMed     Abstract available
     
     
     
154. LEE EK, Xiong N, Krasner C, Polak M, et al
     Phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair proficient recurrent or persistent endometrial cancer.
     Gynecol Oncol. 2025;198:1-8.
     PubMed     Abstract available
     
     
     
155. WAGAR MK, Reetz E, Huang D, Kao MJ, et al
     Patterns of primary metastasis and recurrence in mismatch repair deficiency and p53 abnormal endometrial carcinoma.
     Gynecol Oncol. 2025;197:171-178.
     PubMed     Abstract available
     
     
     
156. WAGGONER RM, Mahoney RP, Nathan D, Zell JA, et al
     Assessing preventive gynecologic decisions in individuals with Lynch syndrome.
     Gynecol Oncol. 2025;197:163-170.
     PubMed     Abstract available
     
     
     
157. BYRNE ME, Selenica P, Dessources K, Da Cruz Paula A, et al
     Peritoneal washings analysis in endometrial cancer: Comparison of somatic mutation detection with panel sequencing and traditional cytology.
     Gynecol Oncol. 2025;197:155-162.
     PubMed     Abstract available
     
     
     
158. XIAO Y, Pang J, Zhou Y, Lu J, et al
     FRalpha expression in advanced endometrial carcinoma: Clinicopathological, molecular, and prognosis correlates.
     Gynecol Oncol. 2025;197:146-154.
     PubMed     Abstract available
     
     
     
159. EVANS E, Dholakia J, Abraham J, Hinton A, et al
     Whole-exome sequencing provides assessment of homologous recombination deficiency for identification of PARPi-responsive ovarian tumors.
     Gynecol Oncol. 2025;197:139-145.
     PubMed     Abstract available
     
     
     
160. MOUFARRIJ S, Dopeso H, Brown DN, Green H, et al
     TROP2 expression and therapeutic targeting in uterine carcinosarcoma.
     Gynecol Oncol. 2025;197:129-138.
     PubMed     Abstract available
     
     
     
161. KARLSSON E, Vorobii O, Silins I, Sundstrom Poromaa I, et al
     Splenectomy as an indicator for ovarian cancer spread and complete cytoreduction.
     Gynecol Oncol. 2025;197:121-128.
     PubMed     Abstract available
     
     
     
162. KEVERLINE KJ, Hill B, Hom-Tedla M, Jacobs M, et al
     Impact of mismatch repair (MMR) status on recurrence in high intermediate risk endometrial cancer.
     Gynecol Oncol. 2025;197:116-120.
     PubMed     Abstract available
     
     
     
163. ETTORRE VM, Bellone S, Greenman M, McNamara B, et al
     A phase 2 trial of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability (NCT02899793): Updated survival and response analyses.
     Gynecol Oncol. 2025;197:110-115.
     PubMed     Abstract available
     
     
     
164. SUH-BURGMANN E, Hung YY, Finertie H, Zhong H, et al
     Association of endometrial cancer epigenetic mismatch repair deficiency with clinicopathologic factors and survival in a large, diverse community-based cohort.
     Gynecol Oncol. 2025;197:102-109.
     PubMed     Abstract available
     
     
     
165. THAKER PH, Richardson DL, Hagemann AR, Holloway RW, et al
     OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer.
     Gynecol Oncol. 2025 May 2:S0090-8258(25)00797.
     PubMed     Abstract available
     
     
     
166. ALIMENA S, Reid H, Bercow A, Feltmate C, et al
     Trends in sentinel lymph node evaluation for vulvar melanoma in the United States from 2012 to 2018.
     Gynecol Oncol. 2025;196:175-181.
     PubMed     Abstract available
     
     
     
167. CORNEL KMC, Mehta MP, Swift BE, Covens A, et al
     The use of indocyanine green (ICG) for sentinel lymph node detection in vulvar cancer.
     Gynecol Oncol. 2025;196:146-151.
     PubMed     Abstract available
     
     
     
168. STUEBS FA, Knoll A, Hartmann A, Matek C, et al
     Trop2-expression in primary vulvar squamous cell carcinoma.
     Gynecol Oncol. 2025;196:78-84.
     PubMed     Abstract available
     
     
     April 2025
169. LOUKOVAARA M, Pasanen A, Butzow R
     Molecular subgroup-specific prognostic value of semiquantitative lymphovascular space invasion in early-stage endometrioid endometrial cancer.
     Gynecol Oncol. 2025;197:96-101.
     PubMed     Abstract available
     
     
     
170. BAE J, Kim U, Paik ES, Lim MC, et al
     Oncologic outcomes of minimally invasive surgery vs. abdominal hysterectomy in patients with low-risk, early-stage cervical cancer: A retrospective analysis of KGOG 1028 data based on SHAPE trial eligibility criteria.
     Gynecol Oncol. 2025;197:91-95.
     PubMed     Abstract available
     
     
     
171. JOHNSON CR, Aryasomayajula C, Francoeur AA, Stewart C, et al
     Pathogenic germline variants among women with uterine cancer by ancestry: A commercial laboratory collaborative research registry study.
     Gynecol Oncol. 2025;197:83-90.
     PubMed     Abstract available
     
     
     
172. POVEDA A, Lheureux S, Colombo N, Cibula D, et al
     Maintenance olaparib monotherapy in patients with platinum-sensitive relapsed ovarian cancer without a germline BRCA1 and/or BRCA2 mutation: Final overall survival results from the OPINION trial.
     Gynecol Oncol. 2025;197:74-82.
     PubMed     Abstract available
     
     
     
173. YOU B, Anderson C, Cecere SC, Carrot A, et al
     Impact of adding the immune checkpoint inhibitor atezolizumab to first-line chemotherapy on progression-free survival in poor-prognosis ovarian cancer: A retrospective analysis from the IMagyn050 trial.
     Gynecol Oncol. 2025;197:66-73.
     PubMed     Abstract available
     
     
     
174. FITZGERALD KJ, Konstantinopoulos P, Matulonis U, Liu J, et al
     A phase I clinical trial of radiation therapy, durvalumab and tremelimumab in recurrent gynecologic cancer.
     Gynecol Oncol. 2025;197:51-56.
     PubMed     Abstract available
     
     
     
175. LEON-CASTILLO A, Horeweg N, Peters EEM, Ter Haar N, et al
     Pattern of recurrence of the molecular subgroups in stage I high-grade endometrial cancer.
     Gynecol Oncol. 2025;197:43-50.
     PubMed     Abstract available
     
     
     
176. XIE J, Maguire FB, Hofer BM, Cooley JJP, et al
     Disparities in hysterectomy-corrected endometrial cancer incidence trends by histologic subtype among racial/ethnic groups in California, 2012-2019.
     Gynecol Oncol. 2025;197:34-42.
     PubMed     Abstract available
     
     
     
177. FRIEDMAN EL, Guo XM, Furey KB, Lee AJ, et al
     Temporal trends of sentinel lymph node biopsy without lymphadenectomy at cervical cancer surgery.
     Gynecol Oncol. 2025;196:182-191.
     PubMed     Abstract available
     
     
     
178. GRCEVICH L, Chuzhyk O, Giannini A, McGree ME, et al
     Safety and feasibility of same day discharge for robotic hysterectomy and staging for endometrial cancer.
     Gynecol Oncol. 2025;197:19-24.
     PubMed     Abstract available
     
     
     
179. WILKE RN, Wu CF, Kanbergs A, Bercow AS, et al
     Disparities in facility-level adoption of minimally invasive interval debulking surgery for advanced ovarian cancer.
     Gynecol Oncol. 2025;197:11-18.
     PubMed     Abstract available
     
     
     
180. RIOS-DORIA E, Parker EU, Kohrn BF, Pike M, et al
     TP53 somatic evolution in the normal endometrium of Black and White individuals.
     Gynecol Oncol. 2025;197:1-10.
     PubMed     Abstract available
     
     
     
181. MORRIS DH, Kosmacki A, Tolby L, Marx C, et al
     Integration of a lifestyle modification intervention for women with overweight and obesity in a gynecologic oncology practice.
     Gynecol Oncol. 2025;196:168-174.
     PubMed     Abstract available
     
     
     
182. BORCINOVA M, Kohler C, Nemejcova K, Zapardiel I, et al
     Preoperative tumour size assessment in patients with early-stage cervical cancer: Final results of the SENTIX study.
     Gynecol Oncol. 2025;196:160-167.
     PubMed     Abstract available
     
     
     
183. RAIMONDO D, Raffone A, Maletta M, Restaino S, et al
     Hysterectomy or not for borderline ovarian tumor in menopause?
     Gynecol Oncol. 2025;196:152-159.
     PubMed     Abstract available
     
     
     
184. ZELISSE HS, Snijders MLH, Groenendijk FH, Halfwerk JBG, et al
     The prognostic potential of molecular subtypes including estrogen receptor status in endometrioid ovarian cancer.
     Gynecol Oncol. 2025;196:137-145.
     PubMed     Abstract available
     
     
     
185. METTALA T, Joutsiniemi T, Huvila J, Hietanen S, et al
     Genetic predictors of unexpected recurrence in low-risk endometrial cancer: A comprehensive genomic analysis reveals FGFR2 as a risk factor and a rare fatal POLE-mutated recurrence.
     Gynecol Oncol. 2025;196:129-136.
     PubMed     Abstract available
     
     
     
186. HABLASE R, Steinke J, Aslam A, Jose R, et al
     Anastomotic leakage in colorectal and ovarian cancer resections: A comparative cohort study.
     Gynecol Oncol. 2025;196:121-128.
     PubMed     Abstract available
     
     
     
187. GONZALEZ-BOSQUET J, Shahi M, Yadav S, Kanwar N, et al
     ECPPF stratification identifies occult high-risk subgroups in stage I, grade 1 or 2,
     Gynecol Oncol. 2025;196:113-120.
     PubMed     Abstract available
     
     
     
188. COSGROVE CM, Suarez AA, Haight PJ, Villacres A, et al
     Exploring endometrial cancer risk stratification by copy number assessment.
     Gynecol Oncol. 2025;196:99-106.
     PubMed     Abstract available
     
     
     
189. KAHN RM, Murphy K, Patel T, Yeoshoua E, et al
     Three-dimensional volumetric rendering on augmented reality headsets for ovarian cancer cytoreduction planning: A Memorial Sloan Kettering Cancer Center Team Ovary study.
     Gynecol Oncol. 2025;196:107-112.
     PubMed     Abstract available
     
     
     
190. VARGIU V, Santullo F, Scambia G, Naldini A, et al
     STOMA study SToma-leak ratio in advanced ovarian cancer surgery: Results of a restrictive policy on the use of protective stoMAs.
     Gynecol Oncol. 2025;196:92-98.
     PubMed     Abstract available
     
     
     
191. BUJNAK AC, Greenberg D, Chang J, Tseng J, et al
     Adjuvant treatment in stage I clear cell endometrial carcinoma: A population-based study of survival outcomes.
     Gynecol Oncol. 2025;196:85-91.
     PubMed     Abstract available
     
     
     
192. WOLF B, Trantaki DS, Horn LC, Aktas B, et al
     Preoperative conization in cervical cancer patients undergoing open abdominal radical hysterectomy: Results from a propensity-score matched study.
     Gynecol Oncol. 2025;196:69-77.
     PubMed     Abstract available
     
     
     
193. WESTRICK AC, Bailey Z, Schlumbrecht M
     Influence of residential segregation and health provider density on advanced stage endometrial cancer diagnoses.
     Gynecol Oncol. 2025;196:62-68.
     PubMed     Abstract available
     
     
     
194. HAGHIGHAT R, Ozarowski AL, Liu YL, Frey MK, et al
     MUTYH: Possibly another important gene in ovarian cancer?
     Gynecol Oncol. 2025;196:59-61.
     PubMed    
     
     
     
195. CIOFFI R, Fruscio R, Sabetta G, Bergamini A, et al
     Consolidation courses in low-risk gestational trophoblastic neoplasia and relapse rate: A MITO-9 retrospective study.
     Gynecol Oncol. 2025;196:54-58.
     PubMed     Abstract available
     
     
     
196. CHAM S, Kumar A, Walter LC, Lichtman S, et al
     Understanding frailty and the role of patient-centered care for older adults with gynecologic cancer.
     Gynecol Oncol. 2025;196:42-53.
     PubMed     Abstract available
     
     
     
197. TA QD, Do C, Sharma K, Sorooshian HZ, et al
     Reduced dosing of lenvatinib with pembrolizumab for advanced endometrial cancer.
     Gynecol Oncol. 2025;196:36-41.
     PubMed     Abstract available
     
     
     
198. LEATH CA 3RD, Deng W, Mell LK, Richardson DL, et al
     Incorporation of triapine (T) to cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial.
     Gynecol Oncol. 2025;195:122-133.
     PubMed     Abstract available
     
     
     
199. BRINK GJ, Groeneweg JW, van der Ploeg P, Jonges GN, et al
     Signal transduction pathway activity in adult-type granulosa cell tumor samples.
     Gynecol Oncol. 2025;195:6-11.
     PubMed     Abstract available
     
     
     
200. PODDER V, Slomovitz BM
     Rethinking metformin in advanced endometrial cancer: Scientific humility, translational challenges, and the urgency for equity.
     Gynecol Oncol. 2025;195:A1-A2.
     PubMed    
     
     
     March 2025
201. LORUSSO D, Oaknin A, Borges GS, Damian F, et al
     Cemiplimab plus peltopepimut-S vaccine in recurrent cervical cancer: A phase 2 clinical trial.
     Gynecol Oncol. 2025;196:28-35.
     PubMed     Abstract available
     
     
     
202. XIE H, Sun L, Yao S, Tian X, et al
     Therapeutically targeting endometrial cancer in preclinical models by ICAM1 antibody-drug conjugates.
     Gynecol Oncol. 2025;196:16-27.
     PubMed     Abstract available
     
     
     
203. KIM J, Jang J, Lim MC, Kim MH, et al
     Which factors predict the effectiveness of adjuvant treatment in patients with non-high-risk early-stage cervical cancer? Ancillary analysis of KGOG-1028.
     Gynecol Oncol. 2025;196:10-15.
     PubMed     Abstract available
     
     
     
204. MATULONIS UA, Herrstedt J, Oza A, Mahner S, et al
     ENGOT-OV16/NOVA trial of niraparib in recurrent ovarian cancer: Survival and long-term safety.
     Gynecol Oncol. 2025;195:192-199.
     PubMed     Abstract available
     
     
     
205. BUJNAK AC, Solaru SA, Tewari K
     Clinical applications of antibody drug conjugates for gynecologic malignancies: Review of available medicines and emerging therapeutics.
     Gynecol Oncol. 2025;195:180-191.
     PubMed     Abstract available
     
     
     
206. ETHIER JL, Shephard C, Granados DP, Dutta N, et al
     Comparative efficacy and safety of low-dose versus high-dose bevacizumab in ovarian cancer: An indirect treatment comparison.
     Gynecol Oncol. 2025;196:1-9.
     PubMed     Abstract available
     
     
     
207. JOHANNET P, Flint M, Chui MH, Konner J, et al
     Patient outcomes in advanced ovarian cancer treated with an anti-FOLR1 antibody-drug conjugate.
     Gynecol Oncol. 2025;195:173-179.
     PubMed     Abstract available
     
     
     
208. LI Y, Wu M, Liu Q, Huang C, et al
     Development and validation of an ovarian cancer risk assessment tool for first-degree relatives of patients in the Chinese population.
     Gynecol Oncol. 2025;195:165-172.
     PubMed     Abstract available
     
     
     
209. LEE EK, Kolin DL, Matulonis UA, Erickson BK, et al
     Diagnostic and therapeutic advances for HER2-expressing or amplified gynecologic cancers.
     Gynecol Oncol. 2025;195:152-164.
     PubMed     Abstract available
     
     
     
210. DEMARI JA, Glassman D, Smith S, Darby JP, et al
     Endometrial cancer somatic testing practice patterns among gynecologic oncologists.
     Gynecol Oncol. 2025;195:149-151.
     PubMed    
     
     
     
211. SULLIVAN MW, Chui MH, Selenica P, Long Roche K, et al
     Anaplastic carcinoma of the ovary: A single-institution experience and molecular analysis.
     Gynecol Oncol. 2025;195:144-148.
     PubMed     Abstract available
     
     
     
212. DE BONDT D, Naslazi E, Jansen E, Kupets R, et al
     Validating the predicted impact of HPV vaccination on HPV prevalence, cervical lesions, and cervical cancer: A systematic review of population level data and modelling studies.
     Gynecol Oncol. 2025;195:134-143.
     PubMed     Abstract available
     
     
     
213. CARUSO G, Kumar A, Langstraat CL, McGree ME, et al
     Racial/ethnic, socioeconomic, and healthcare access disparities in achieving textbook oncologic outcome in advanced ovarian cancer.
     Gynecol Oncol. 2025;195:106-114.
     PubMed     Abstract available
     
     
     
214. SALINARO J, Singh K, Sands N, Gill V, et al
     Distribution and concordance of HER2 scores in endometrial and ovarian cancer.
     Gynecol Oncol. 2025;195:115-121.
     PubMed     Abstract available
     
     
     
215. ENGH A, Rueegg CS, Bjerre Trent PK, Opheim LO, et al
     Physical activity and lower extremity lymphedema among endometrial cancer survivors: A population-based cross-sectional study.
     Gynecol Oncol. 2025;195:82-88.
     PubMed     Abstract available
     
     
     
216. LINDEMANN K, Siegenthaler F, Lande KT, Casas-Arozamena C, et al
     Prognostic value of assessing ctDNA in patients with endometrial carcinoma - an international multicenter study.
     Gynecol Oncol. 2025;195:98-105.
     PubMed     Abstract available
     
     
     
217. ZAMMARRELLI WA 3RD, Nandakumar S, Kertowidjojo E, Nguyen B, et al
     The genomic landscape of distant metastatic endometrial cancer.
     Gynecol Oncol. 2025;195:89-97.
     PubMed     Abstract available
     
     
     
218. TYAN K, Liu KX, Smart AC, Feltmate CM, et al
     Role of adjuvant radiotherapy modality on clinical outcomes for early-stage uterine carcinosarcoma.
     Gynecol Oncol. 2025;195:75-81.
     PubMed     Abstract available
     
     
     
219. CARTER J, Huang HQ, Monk BJ, Kim YB, et al
     Evaluation of physical function and quality of life before and after nonradical surgical therapy for stage IA1 and IA2-IB1 cervical cancer (GOG-0278).
     Gynecol Oncol. 2025;195:50-58.
     PubMed     Abstract available
     
     
     
220. BAE-JUMP VL, Sill MW, Gehrig PA, Merker JD, et al
     A randomized phase II/III study of paclitaxel/carboplatin/metformin versus paclitaxel/carboplatin/placebo as initial therapy for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer: An NRG oncology/GOG study.
     Gynecol Oncol. 2025;195:66-74.
     PubMed     Abstract available
     
     
     
221. COVENS A, Huang HQ, Monk BJ, Kim YB, et al
     Evaluation of efficacy and fertility after nonradical surgical therapy (extra fascial hysterectomy or cone biopsy, with pelvic lymphadenectomy) for stage IA1, IA2, and IB1 cervical cancer (GOG-0278).
     Gynecol Oncol. 2025;195:59-65.
     PubMed     Abstract available
     
     
     
222. LA TORRE F, Hurni Y, Farsi E, Nardi E, et al
     Adenomyosis associated with endometrial cancer: Possible correlation with pathological, immunohistochemical and molecular characteristics.
     Gynecol Oncol. 2025;195:45-49.
     PubMed     Abstract available
     
     
     
223. LI X, Wang Z, Man X, Dai X, et al
     Research advances CRISPR gene editing technology generated models in the study of epithelial ovarian carcinoma.
     Gynecol Oncol. 2025;195:34-44.
     PubMed     Abstract available
     
     
     
224. HICKS A, Borho L, Elishaev E, Berger J, et al
     All-cause mortality and neighborhood social vulnerability among women with ovarian cancer.
     Gynecol Oncol. 2025;195:26-33.
     PubMed     Abstract available
     
     
     
225. MARCHETTI C, Ergasti R, Capomacchia FM, Giannarelli D, et al
     Integrating clinical-molecular data to predict PARP inhibitors efficacy in advanced ovarian cancer patients after interval cytoreductive surgery.
     Gynecol Oncol. 2025;195:16-25.
     PubMed     Abstract available
     
     
     
226. FUCA G, Dell'Acqua C, Peruffo B, Lalli G, et al
     WRN dependency in dMMR/MSI-H endometrial cancer: Clinical perspectives of a novel synthetic lethality strategy.
     Gynecol Oncol. 2025;195:12-15.
     PubMed    
     
     
     
227. DINKINS KG, Lee GM, Arend RC, Leath CA 3rd, et al
     Trends in FDA approvals of gynecologic oncology therapeutics from 2019 to 2024.
     Gynecol Oncol. 2025;194:153-158.
     PubMed     Abstract available
     
     
     
228. HERZOG TJ, Liao JB, Finkelstein K, Willmott L, et al
     An open-label randomized active-controlled phase II clinical study to assess the efficacy and safety of afuresertib plus paclitaxel versus paclitaxel in patients with platinum-resistant ovarian cancer (PROFECTA-II/GOG-3044).
     Gynecol Oncol. 2025;194:145-152.
     PubMed     Abstract available
     
     
     
229. WENZEL L, McKinney C, Jensen S, Peipert D, et al
     Ensuring relevance and equity in patient reported outcomes (PROs) in endometrial cancer: The SGO promote study (Patient Reported Outcomes Measurement Opportunities Through Equity).
     Gynecol Oncol. 2025;194:137-144.
     PubMed     Abstract available
     
     
     
230. VELASQUEZ J, Mohammed-Norgan M, Scheiber A, Chalif J, et al
     Cross-language insights: Comparing Spanish and English-language cervical cancer content on TikTok.
     Gynecol Oncol. 2025;194:131-136.
     PubMed     Abstract available
     
     
     
231. LI J, Welte T, Calzoncinth K, Vuttaradhi VK, et al
     An inducible FOXL2-dependent mouse model of ovarian adult type granulosa cell tumor.
     Gynecol Oncol. 2025;194:125-130.
     PubMed     Abstract available
     
     
     
232. DEBBICHE I, Wang CC, Gomez-Roas M, Foley OW, et al
     Rest assured: High sleep efficiency reduces postoperative complications and opioid prescriptions in patients undergoing surgeries with gynecologic oncologists.
     Gynecol Oncol. 2025;194:119-124.
     PubMed     Abstract available
     
     
     
233. VAN VELZEN AF, Tulling AJ, van Poelgeest MIE, Bosse T, et al
     Predicting lymph node metastases in three different vulvar squamous cell carcinoma subgroups.
     Gynecol Oncol. 2025;194:86-90.
     PubMed     Abstract available
     
     
     
234. ZANNONI GF, Angelico G, Spadola S, Bragantini E, et al
     Chemotherapy Response Score (CRS): A comprehensive review of its prognostic and predictive value in High-Grade Serous Carcinoma (HGSC).
     Gynecol Oncol. 2025;194:1-10.
     PubMed     Abstract available
     
     
     
235. ESKANDER RN
     Implications of the platinum-free interval in endometrial cancer: A legacy worth leaving behind?
     Gynecol Oncol. 2025;194:A3-A4.
     PubMed    
     
     
     February 2025
236. WALKER AR, Leite S, Chen YS, Huepenbecker SP, et al
     Sentinel lymph node biopsy at the time of hysterectomy for early-stage cervical cancer: A cost-effectiveness analysis.
     Gynecol Oncol. 2025;195:1-5.
     PubMed     Abstract available
     
     
     
237. ASARE A, Previs RA, Spinosa D, Fellman B, et al
     Bevacizumab beyond progression: Impact of subsequent bevacizumab re-treatment in patients with ovarian, fallopian tube, and peritoneal cancer after progression.
     Gynecol Oncol. 2025;194:112-118.
     PubMed     Abstract available
     
     
     
238. HAIGHT PJ, Sanchez M, Thomas SM, Smitherman C, et al
     Platinum-free interval and response to platinum retreatment or lenvatinib/pembrolizumab in patients with recurrent endometrial cancer: A real-world endometrial cancer molecularly targeted therapy consortium cohort study.
     Gynecol Oncol. 2025;194:98-104.
     PubMed     Abstract available
     
     
     
239. NOLIN AC, Atkins SL, Myers ER, Wentzensen N, et al
     Ultrasound-based versus immediate biopsy-based management of postmenopausal bleeding in non-Hispanic Black and non-Hispanic White individuals.
     Gynecol Oncol. 2025;194:105-111.
     PubMed     Abstract available
     
     
     
240. MACDUFFIE E, Kernell C, George J, Bvochora-Nsingo M, et al
     Efficacy of induction chemotherapy during the COVID-19 pandemic for treatment of locally advanced cervical cancer in Botswana.
     Gynecol Oncol. 2025;194:91-97.
     PubMed     Abstract available
     
     
     
241. HAIGHT P, Bilbe C, Riedinger C, Backes F, et al
     Defining "enlarged" sentinel lymph nodes in the setting of endometrial cancer: What is the size cut-off?
     Gynecol Oncol. 2025;194:80-85.
     PubMed     Abstract available
     
     
     
242. ALVERO AB, Wu S, Farrell A, Kim S, et al
     Exploring the differences between BRCA mutated and HRwild-type high grade serous ovarian cancer: A multiomic analysis.
     Gynecol Oncol. 2025;194:71-79.
     PubMed     Abstract available
     
     
     
243. SUN H, Huo X, Bi X, Cao D, et al
     Exosome transmit the ability of migration and invasion in heterogeneous ovarian cancer cells by regulating autophagy via targeting hsa-miR-328.
     Gynecol Oncol. 2025;194:60-70.
     PubMed     Abstract available
     
     
     
244. MATSUO K, Agarwal J, Chen L, Furey KB, et al
     Histology-specific prognostic significance of isolated tumor cells, micrometastases, and macrometastases in endometrial cancer.
     Gynecol Oncol. 2025;194:51-59.
     PubMed     Abstract available
     
     
     
245. TUBRIDY EA, Campbell A, Mulugeta-Gordon L, Andriani L, et al
     Impact of telehealth legislation on gynecologic oncology services: Policy updates.
     Gynecol Oncol. 2025;194:48-50.
     PubMed    
     
     
     
246. GAILLARD S, Verma N, Berg M, Harrison J, et al
     A clinical study of tremelimumab, alone or in combination with olaparib, for recurrent epithelial ovarian cancer.
     Gynecol Oncol. 2025;194:41-47.
     PubMed     Abstract available
     
     
     
247. CORTES-SALGADO A, Moreno-Moreno E, Carretero-Barrio I, Caniego-Casas T, et al
     HER2 expression in a molecularly defined cohort of endometrial cancer patients: The SPECTRUM study.
     Gynecol Oncol. 2025;194:33-40.
     PubMed     Abstract available
     
     
     
248. KIM J, Park SY, Kim JH, Lee SW, et al
     Real-world efficacy and toxicity of olaparib maintenance therapy in Korean ovarian cancer patients with an exploratory analysis of BRCA mutations.
     Gynecol Oncol. 2025;194:25-32.
     PubMed     Abstract available
     
     
     
249. ROMERO IL, Lengyel E, Wahner Hendrickson AE, Rodriguez GC, et al
     Metformin for patients with advanced stage ovarian cancer: A randomized phase II placebo-controlled trial.
     Gynecol Oncol. 2025;194:18-24.
     PubMed     Abstract available
     
     
     
250. VALENZA C, Mongillo M, Visconti MV, Katrini J, et al
     Rechallenge with platinum-based chemotherapy in patients with platinum-resistant ovarian carcinoma: A cohort study.
     Gynecol Oncol. 2025;194:11-17.
     PubMed     Abstract available
     
     
     
251. CORVIGNO S, Fernebro J, Karlsson JS, Mezheieusky A, et al
     High prevalence of FAP+ cancer-associated fibroblasts predicts poor outcome in patients with high-grade serous ovarian cancer with high CD8 T-cell density.
     Gynecol Oncol. 2025;193:148-155.
     PubMed     Abstract available
     
     
     
252. STUEBS FA, Knoll A, Hartmann A, Leikauf LS, et al
     PD-L1-Expression in primary and recurrent vulvar squamous cell cancer.
     Gynecol Oncol. 2025;193:98-104.
     PubMed     Abstract available
     
     
     
253. HOROWITZ NS, St Laurent JD, Berkowitz RS
     Prevention of gestational trophoblastic neoplasia with actinomycin -D at the time of evacuation: A matter of routine practice or reserve for special circumstances?
     Gynecol Oncol. 2025;193:A1-A2.
     PubMed    
     
     
     January 2025
254. MAKI PM, Rubin LH, Krejany EO, Brand A, et al
     What happens after menopause? (WHAM): A prospective controlled study of cognition 24 months after premenopausal risk-reducing salpingo-oophorectomy.
     Gynecol Oncol. 2025;193:141-147.
     PubMed     Abstract available
     
     
     
255. KIM YJ, Lee J, Park S, Kim YM, et al
     The value of magnetic resonance imaging in predicting vesicovaginal fistula in cervical cancer with bladder invasion treated with definitive chemoradiotherapy.
     Gynecol Oncol. 2025;193:136-140.
     PubMed     Abstract available
     
     
     
256. CLEMENTS A, Enserro D, Strickland KC, Previs R, et al
     Molecular classification of endometrial cancers (EC) and association with relapse-free survival (RFS) and overall survival (OS) outcomes: Ancillary analysis of GOG-0258.
     Gynecol Oncol. 2025;193:119-129.
     PubMed     Abstract available
     
     
     
257. O'MALLEY DM, Bariani GM, Cassier PA, Marabelle A, et al
     Pembrolizumab in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) and non-MSI-H/non-dMMR advanced endometrial cancer: Phase 2 KEYNOTE-158 study results.
     Gynecol Oncol. 2025;193:130-135.
     PubMed     Abstract available
     
     
     
258. TOBONI MD, Dinkins K, Wu S, Mattox T, et al
     Not all uterine carcinosarcomas are created equal: Survival outcomes according to molecular characterization of uterine carcinosarcoma.
     Gynecol Oncol. 2025;193:89-97.
     PubMed     Abstract available
     
     
     
259. SCHAAFSMA M, Schuurman TN, Siebers AG, Bekkers RLM, et al
     Cost-effectiveness of an additional hysterectomy after initially conservative treatment for cervical adenocarcinoma in situ.
     Gynecol Oncol. 2025;193:113-118.
     PubMed     Abstract available
     
     
     
260. UBERTI EMH, de Freitas Medeiros LR, Cardoso RB, Muller KP, et al
     Primary prevention of post-molar gestational trophoblastic neoplasia in high-risk complete hydatidiform mole: A single-dose prophylactic actinomycin D, associated with uterine evacuation - a long retrospective cohort study.
     Gynecol Oncol. 2025;193:105-112.
     PubMed     Abstract available
     
     
     
261. DE VITIS LA, Reyes-Baez FE, Schivardi G, Shahi M, et al
     Cervical stromal invasion and molecular characterization in stage II-IV endometrial cancers.
     Gynecol Oncol. 2025;193:81-88.
     PubMed     Abstract available
     
     
     
262. WANG H, Zhu J, Zou D, Rao Q, et al
     Multicenter study of ovarian cancer score for diagnosing ovarian cancer.
     Gynecol Oncol. 2025;193:58-64.
     PubMed     Abstract available
     
     
     
263. AHMED J, Stephen B, Khawaja MR, Yang Y, et al
     A phase I study of temsirolimus in combination with metformin in patients with advanced or recurrent endometrial cancer.
     Gynecol Oncol. 2025;193:73-80.
     PubMed     Abstract available
     
     
     
264. MIRZA HB, Hunt A, Ennis DP, McDermott J, et al
     Spatial transcriptomic analysis reveals significant differences in tumor microenvironment in HPV-dependent and HPV-independent vulvar squamous cell carcinoma.
     Gynecol Oncol. 2025;193:65-72.
     PubMed     Abstract available
     
     
     
265. LEIJTENS L, Piek J, Verrijssen AS, Rijkaart D, et al
     Thromboprophylaxis in patients with locally advanced cervical cancer treated with chemoradiation and brachytherapy.
     Gynecol Oncol. 2025;193:41-48.
     PubMed     Abstract available
     
     
     
266. RICCIUTI J, Liu Q, Khan ANMNH, Joseph JM, et al
     Prognostic significance of serum complement activation, neutrophil extracellular traps and extracellular DNA in newly diagnosed epithelial ovarian cancer.
     Gynecol Oncol. 2025;193:49-57.
     PubMed     Abstract available
     
     
     
267. BOGANI G, Moore KN, Ray-Coquard I, Lorusso D, et al
     Incorporating immune checkpoint inhibitors in epithelial ovarian cancer.
     Gynecol Oncol. 2025;193:30-40.
     PubMed     Abstract available
     
     
     
268. WALKER AR, Leite S, Taylor N, Graul A, et al
     Lymph node assessment at the time of robotic hysterectomy for endometrial intraepithelial neoplasia: A cost-effectiveness analysis.
     Gynecol Oncol. 2025;193:24-29.
     PubMed     Abstract available
     
     
     
269. SIEGENTHALER F, Imboden S, Buchi C, Christe L, et al
     Added prognostic value of sentinel lymph node mapping in endometrial cancer to molecular subgroups.
     Gynecol Oncol. 2025;193:12-19.
     PubMed     Abstract available
     
     
     
270. VOSS FO, Fons G, Bruggink AH, Wenzel HHB, et al
     Prevalence and impact of vulvar lesions diagnosed prior to vulvar squamous cell carcinoma: A population-based cohort study.
     Gynecol Oncol. 2025;192:163-170.
     PubMed     Abstract available
     
     
     
271. MARINO G, Marchetta L, Negri S, Testa F, et al
     Oncologic and fertility outcomes in patients with juvenile granulosa cell tumor - a retrospective single centre analysis.
     Gynecol Oncol. 2025;192:89-93.
     PubMed     Abstract available
     
     
     December 2024
272. NEILSON A, Jamieson A, Chiu D, Leung S, et al
     Serum CA125 levels in the context of ProMisE molecular classification provides pre-operative prognostic information that can direct endometrial cancer management.
     Gynecol Oncol. 2024;193:1-11.
     PubMed     Abstract available
     
     
     
273. MADDY BP, Tischer KM, McGree ME, Fought AJ, et al
     Implementation of enhanced recovery protocol did not increase rates of acute kidney injury in open gynecologic oncology surgery: A single-institution experience.
     Gynecol Oncol. 2024;192:181-188.
     PubMed     Abstract available
     
     
     
274. VOS JAM, Vos MC, van Lonkhuijzen LRCW, van de Poll-Franse LV, et al
     Less is more: The benefits of reduced follow-up in gynecologic cancers.
     Gynecol Oncol. 2024;192:178-180.
     PubMed    
     
     
     
275. LIU YL, Praiss AM, Chiang S, Devereaux K, et al
     Gestational trophoblastic neoplasm: Patient outcomes and clinical pearls from a multidisciplinary referral center.
     Gynecol Oncol. 2024;192:171-177.
     PubMed     Abstract available
     
     
     
276. KONUMA M, Ikeda T, Mitoma T, Shirakawa S, et al
     Effectiveness of exercise therapy on chemotherapy-induced peripheral neuropathy in patients with ovarian cancer: A scoping review.
     Gynecol Oncol. 2024;192:155-162.
     PubMed     Abstract available
     
     
     
277. AZAIS H, Brochard C, Taly V, Benoit L, et al
     Prognostic value of circulating tumor DNA at diagnosis and its early decrease after one cycle of neoadjuvant chemotherapy for patients with advanced epithelial ovarian cancer. An ancillary analysis of the CHIVA phase II GINECO trial.
     Gynecol Oncol. 2024;192:145-154.
     PubMed     Abstract available
     
     
     
278. NGUYEN T, Yi Y, Morron S, Brittain D, et al
     Living in a food desert in Louisiana and its effects on gynecologic cancer outcomes.
     Gynecol Oncol. 2024;192:137-144.
     PubMed     Abstract available
     
     
     
279. MIRZA MR, Bjorge L, Marme F, Christensen RD, et al
     Palbociclib plus letrozole in estrogen receptor-positive advanced/recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3/PALEO trial.
     Gynecol Oncol. 2024;192:128-136.
     PubMed     Abstract available
     
     
     
280. GRAVES S, Sullivan MW, Adkoli A, Zhou Q, et al
     Association between genomic instability score and progression-free/overall survival in patients with newly diagnosed non-BRCA1/2 ovarian cancer.
     Gynecol Oncol. 2024;192:120-127.
     PubMed     Abstract available
     
     
     
281. CASTELLANO T, Lara OD, McCormick C, Chase D, et al
     Clinical trial screening in gynecologic oncology: Defining the need and identifying best practices.
     Gynecol Oncol. 2024;192:111-119.
     PubMed     Abstract available
     
     
     
282. PREVIS RA, Strickland KC, Wallen Z, Ko H, et al
     Analysis of real world FRalpha testing in ovarian, fallopian tube, and primary peritoneal cancers.
     Gynecol Oncol. 2024;192:102-110.
     PubMed     Abstract available
     
     
     
283. COLSON-FEARON D, Viswanathan AN
     Trends in brachytherapy in utilization for vaginal cancer in the United States from 2004 to 2021.
     Gynecol Oncol. 2024;191:228-232.
     PubMed     Abstract available
     
     
     
284. MOUFARRIJ S, Dagher C, Filippova OT, Zhou Q, et al
     Five-year quality-of-life assessment by urinary diversion type after pelvic Exenterations.
     Gynecol Oncol. 2024;191:212-218.
     PubMed     Abstract available
     
     
     
285. FEDERICO A, Lancellotta V, Fragomeni SM, Macchia G, et al
     Surgery after upfront chemoradiation in locally advanced squamous cell vulvar cancer: Analysis of postoperative outcomes and survival.
     Gynecol Oncol. 2024;191:106-113.
     PubMed     Abstract available
     
     
     
286. WONG TY, Adzibolosu NK, Mattei LH, Speak AC, et al
     Disparities in contemporary human papilloma virus vaccination uptake among adult women living in the United States: An All of Us Research Program study.
     Gynecol Oncol. 2024;191:100-105.
     PubMed     Abstract available
     
     
     
287. THAYER EG, Manning-Geist BL
     Following the folate receptor: Expanding targeted treatment options in low grade serous ovarian carcinoma.
     Gynecol Oncol. 2024;191:A1-A2.
     PubMed    
     
     
     November 2024
288. SHU T, Liang Y, Zhang S, Sun T, et al
     The prognostic value of tumor-informed minimal residual disease detection using circulating tumor DNA in first-line treatment of ovarian cancer.
     Gynecol Oncol. 2024;192:94-101.
     PubMed     Abstract available
     
     
     
289. BORHO L, Elishaev E, Bao R, O'Brien E, et al
     Association of neighborhood social vulnerability with ovarian cancer survival.
     Gynecol Oncol. 2024;192:32-39.
     PubMed     Abstract available
     
     
     
290. KLEPPE A, Lindemann K, Kildal W, Tobin KAR, et al
     Prognostic and therapeutic implication of molecular classification including L1CAM expression in high-risk endometrial cancer.
     Gynecol Oncol. 2024;192:80-88.
     PubMed     Abstract available
     
     
     
291. CLASSEN CC, Chivers ML, Brotto LA, Barbera L, et al
     A randomized controlled trial of an online support group addressing psychosexual distress among women treated for gynecologic cancer.
     Gynecol Oncol. 2024;192:73-79.
     PubMed     Abstract available
     
     
     
292. SONAVANE M, Hedlich-Dwyer J, Dal Zotto VL, Tang M, et al
     Repair Assisted Damage Detection (RADD) as a predictive biomarker for immunotherapy response in ovarian cancer.
     Gynecol Oncol. 2024;192:65-72.
     PubMed     Abstract available
     
     
     
293. KHADRAOUI W, Sinnott JA, Meade CE, Plascak J, et al
     Clinical trial enrollment during first course of gynecologic cancer treatment and survival.
     Gynecol Oncol. 2024;192:59-64.
     PubMed     Abstract available
     
     
     
294. MULUGETA-GORDON L, Smith AJB
     Insurance coverage and access to gynecologic oncology: Where are we are now.
     Gynecol Oncol. 2024;192:56-58.
     PubMed     Abstract available
     
     
     
295. FRANCIS KE, Simon S, Gebski V, Joly F, et al
     Adverse events in the placebo arm of SOLO2/ENGOT-Ov21 maintenance trial of olaparib in recurrent ovarian cancer.
     Gynecol Oncol. 2024;192:50-55.
     PubMed     Abstract available
     
     
     
296. POWELL MA, Cibula D, O'Malley DM, Boere I, et al
     Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY).
     Gynecol Oncol. 2024;192:40-49.
     PubMed     Abstract available
     
     
     
297. COLEMAN RL, Lubinga SJ, Shen Q, Walder L, et al
     Cost-effectiveness of dostarlimab plus carboplatin-paclitaxel for primary advanced or recurrent endometrial cancer from a US payer perspective.
     Gynecol Oncol. 2024;192:24-31.
     PubMed     Abstract available
     
     
     
298. DE JAEGHERE EA, Hamerlinck H, Tuyaerts S, Lippens L, et al
     Associations of the gut microbiome with outcomes in cervical and endometrial cancer patients treated with pembrolizumab: Insights from the phase II PRIMMO trial.
     Gynecol Oncol. 2024;191:275-286.
     PubMed     Abstract available
     
     
     
299. VREDE SW, Van Weelden WJ, Bulten J, Gilks CB, et al
     Hormonal biomarkers remain prognostically relevant within the molecular subgroups in endometrial cancer.
     Gynecol Oncol. 2024;192:15-23.
     PubMed     Abstract available
     
     
     
300. MOUFARRIJ S, Lakhman Y, Aghajanian C, Abu-Rustum NR, et al
     Evolutionary pathways in early-stage, non-myoinvasive endometrioid endometrial cancers of no specific molecular profile.
     Gynecol Oncol. 2024;192:8-14.
     PubMed     Abstract available
     
     
     
301. HICKEY M, Nguyen TL, Krejany EO, Domchek SM, et al
     What happens after menopause? (WHAM): Impact of risk-reducing salpingo-oophorectomy on depressive and anxiety symptoms at 24 months.
     Gynecol Oncol. 2024;192:1-7.
     PubMed     Abstract available
     
     
     
302. KILOWSKI KA, Dietrich MF, Xiu J, Baca Y, et al
     KRAS mutations in endometrial cancers: Possible prognostic and treatment implications.
     Gynecol Oncol. 2024;191:299-306.
     PubMed     Abstract available
     
     
     
303. LEE AW, Poynor V, Siddiqui S
     Disparities in ovarian cancer survival among ethnic Asian American populations, 2006-2020.
     Gynecol Oncol. 2024;191:292-298.
     PubMed     Abstract available
     
     
     
304. BOITANO TKL, Blank SV, Havrilesky LJ, Huh WK, et al
     Too much of a good thing? Projecting the need for gynecologic oncologists over the next 20 years.
     Gynecol Oncol. 2024;191:287-291.
     PubMed     Abstract available
     
     
     
305. JAIN D, Zaeim F, Wahidi M, Smith WJ, et al
     Cervical squamous cell carcinoma outcomes across continents: A retrospective study.
     Gynecol Oncol. 2024;190:272-282.
     PubMed     Abstract available
     
     
     
306. PROPPE L, Jaeger A, Goy Y, Petersen C, et al
     Systematic review - Adjuvant radiotherapy of the vulva in primary vulvar cancer.
     Gynecol Oncol. 2024;190:264-271.
     PubMed     Abstract available
     
     
     
307. CHOI YK, Lee JH, Kim YS, Wee CW, et al
     Mid-treatment MRI-based tumor response assessment for tumor recurrence and patient survival in locally advanced adenocarcinoma of the cervix: A retrospective multicenter study of KROG 23-03.
     Gynecol Oncol. 2024;190:222-229.
     PubMed     Abstract available
     
     
     
308. SHIBATA M, Yoshida K, Yokoi A, Suzuki H, et al
     Elucidation of the role of XBP1 in the progression of complete hydatidiform mole to invasive mole through RNA-seq.
     Gynecol Oncol. 2024;190:189-199.
     PubMed     Abstract available
     
     
     
309. NONZEE NJ, Thiel de Bocanegra H, Navarro S, Bastani R, et al
     Impact of management guidelines for abnormal cervical cytology on colposcopy procedure rates among young women.
     Gynecol Oncol. 2024;190:160-166.
     PubMed     Abstract available
     
     
     
310. HEUS C, Stelten S, Kenter GG, Buffart LM, et al
     Body composition and peri- and postoperative complications in patients with gynaecological malignancies: A systematic review.
     Gynecol Oncol. 2024;190:131-138.
     PubMed     Abstract available
     
     
     
311. WEBBER JW, Wollborn L, Mishra S, Vitonis AF, et al
     Serum miRNA improves the accuracy of a multivariate index assay for triage of an adnexal mass.
     Gynecol Oncol. 2024;190:124-130.
     PubMed     Abstract available
     
     
     
312. METCALF CA, Page CE, Stocker BOS, Johnson RL, et al
     Treating new-onset cognitive complaints after risk-reducing salpingo-oophorectomy: A randomized controlled crossover trial of lisdexamfetamine.
     Gynecol Oncol. 2024;190:62-69.
     PubMed     Abstract available
     
     
     
313. MERTEN R, Strnad V, Karius A, Lotter M, et al
     Brachytherapy in vaginal cancer for organ preservation: Clinical outcome and safety from a single center experience.
     Gynecol Oncol. 2024;190:35-41.
     PubMed     Abstract available
     
     
     
314. TEE XR, Hazard E, Latorre-Esteves E, Kohrn BF, et al
     Increased TP53 somatic evolution in peritoneal washes of individuals with BRCA1 germline mutations.
     Gynecol Oncol. 2024;190:18-27.
     PubMed     Abstract available
     
     
     
315. BROWN J
     Hormonal maintenance therapy for advance low grade serous ovarian carcinoma appears to be of benefit - That's a relief!
     Gynecol Oncol. 2024;190:A1-A2.
     PubMed    
     
     
     October 2024
316. VER HOEVE ES, Rumble ME, Gorzelitz JS, Rose SL, et al
     Biobehavioral predictors of mood, pain, fatigue, and insomnia in endometrial cancer survivors.
     Gynecol Oncol. 2024;191:265-274.
     PubMed     Abstract available
     
     
     
317. HUNSBERGER KS, Tewari KS, Monk BJ, Chase DM, et al
     Standard of care treatment for stage IVB cervical cancer: A systematic review and meta-analysis.
     Gynecol Oncol. 2024;191:259-264.
     PubMed     Abstract available
     
     
     
318. MOORE KN, Lorusso D, Oaknin A, Oza A, et al
     Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha-expressing recurrent ovarian cancer: An integrated safety summary.
     Gynecol Oncol. 2024;191:249-258.
     PubMed     Abstract available
     
     
     
319. PENG S, Zheng Y, Liu J, Chen S, et al
     Molecular classification in fertility-sparing treatment of early-stage endometrial cancer: A potential tool for optimizing patient selection.
     Gynecol Oncol. 2024;191:240-248.
     PubMed     Abstract available
     
     
     
320. GARCIA-DONAS J, Redondo A, Santaballa A, Garrigos L, et al
     Phase II clinical trial assessing the efficacy of enzalutamide in advanced non-resectable granulosa cell ovarian tumors: The GREKO III study (GETHI2016-01).
     Gynecol Oncol. 2024;191:233-239.
     PubMed     Abstract available
     
     
     
321. NAGASE Y, Matsuo K, Nakao Y, Hisa T, et al
     Adjuvant therapy de-escalation for stage I uterine leiomyosarcoma: A systematic review and meta-analysis.
     Gynecol Oncol. 2024;191:219-227.
     PubMed     Abstract available
     
     
     
322. LI G, Li X, Yin R, Feng M, et al
     Phase II study of enlonstobart (SG001), a novel PD-1 inhibitor in patients with PD-L1 positive recurrent/metastatic cervical cancer.
     Gynecol Oncol. 2024;191:165-171.
     PubMed     Abstract available
     
     
     
323. HICKEY M, Trainer AH, Krejany EO, Brand A, et al
     What happens after menopause? (WHAM): A prospective controlled study of vasomotor symptoms and menopause-related quality of life 24 months after premenopausal risk-reducing salpingo-oophorectomy (RRSO).
     Gynecol Oncol. 2024;191:201-211.
     PubMed     Abstract available
     
     
     
324. HAIGHT PJ, Lammers S, Kistenfeger Q, Leipold C, et al
     Cold ischemia time and formalin fixation time in endometrial cancer: Should breast cancer guidelines for preanalytical variables be applied to hysterectomy specimens?
     Gynecol Oncol. 2024;191:194-200.
     PubMed     Abstract available
     
     
     
325. YONEMORI K, Boni V, Min KG, Meniawy TM, et al
     Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and combined with abemaciclib, in recurrent/advanced ER-positive endometrioid endometrial cancer: Results from the phase 1a/1b EMBER study.
     Gynecol Oncol. 2024;191:172-181.
     PubMed     Abstract available
     
     
     
326. ELAYAPILLAI SP, Dogra S, Lausen J, Parker M, et al
     ATR inhibition increases reliance on PARP-mediated DNA repair revealing an improved therapeutic strategy for cervical cancer.
     Gynecol Oncol. 2024;191:182-193.
     PubMed     Abstract available
     
     
     
327. PLINSINGA ML, Rye S, Jones T, Vagenas D, et al
     Mild symptoms matter: Results from a prospective, longitudinal study on the relationship between symptoms, lymphedema and health-related outcomes post-gynecological cancer.
     Gynecol Oncol. 2024;191:158-164.
     PubMed     Abstract available
     
     
     
328. PERRONE E, Capasso I, Giannarelli D, Trozzi R, et al
     Less is more? Comparison between genomic profiling and immunohistochemistry-based models in endometrial cancer molecular classification: A multicenter, retrospective, propensity-matched survival analysis.
     Gynecol Oncol. 2024;191:150-157.
     PubMed     Abstract available
     
     
     
329. OGASAWARA A, Matsushita H, Tan TZ, Shintani D, et al
     Immunological impact of intraperitoneal and intravenous chemotherapy in ovarian cancer, translational analyses of the Phase 3 iPocc trial.
     Gynecol Oncol. 2024;191:124-131.
     PubMed     Abstract available
     
     
     
330. SAAB R, Fellman BM, Legarreta AF, Meyer LA, et al
     Comparative analysis of hormonal therapy in low-grade endometrial stromal sarcoma: A retrospective study.
     Gynecol Oncol. 2024;191:143-149.
     PubMed     Abstract available
     
     
     
331. PINTO P, Moro F, Alcazar JL, Alessi S, et al
     Prediction of non-resectability in tubo-ovarian cancer patients using Peritoneal Cancer Index - A prospective multicentric study using imaging (ISAAC study).
     Gynecol Oncol. 2024;191:132-142.
     PubMed     Abstract available
     
     
     
332. KONG W, Deng B, Shen X, John C, et al
     Tirzepatide as an innovative treatment strategy in a pre-clinical model of obesity-driven endometrial cancer.
     Gynecol Oncol. 2024;191:116-123.
     PubMed     Abstract available
     
     
     
333. NG ZY, Manchanda R, Lopez A, Obermair A, et al
     The prognosis of stage IA cervical cancer: Subgroup analysis of the SCCAN study.
     Gynecol Oncol. 2024;191:95-99.
     PubMed     Abstract available
     
     
     
334. CARUSO G, Langstraat CL, Kumar A, McGree ME, et al
     Textbook oncologic outcome is an easy-to-use composite quality measure that is strongly associated with survival in advanced-stage ovarian cancer.
     Gynecol Oncol. 2024;191:86-94.
     PubMed     Abstract available
     
     
     
335. RUSHTON T, Krause HB, Samec T, Elliott A, et al
     Characterizing the genomic landscape through the lens of FOLR1 status in low and high grade serous ovarian carcinoma.
     Gynecol Oncol. 2024;191:80-85.
     PubMed     Abstract available
     
     
     
336. LIAO JB, Jejurikar NS, Hitchcock-Bernhardt KM, Gwin WR, et al
     Intraperitoneal immunotherapy with denileukin diftitox (ONTAK) in recurrent refractory ovarian cancer.
     Gynecol Oncol. 2024;191:74-79.
     PubMed     Abstract available
     
     
     
337. BRITTON MC, Izampuye E, Clark M, Ornstein RA, et al
     Diagnostic experiences of Black and White patients with uterine cancer: A qualitative study.
     Gynecol Oncol. 2024;191:67-73.
     PubMed     Abstract available
     
     
     
338. VAZ J, Piver R, Brzezinska B, Suhner J, et al
     Nutrition's checkpoint inhibition: The impact of nutrition on immunotherapy outcomes.
     Gynecol Oncol. 2024;189:129-136.
     PubMed     Abstract available
     
     
     September 2024
339. WAN S, Gao Y, Wu S, Wang H, et al
     Somatic mutation of targeted sequencing identifies risk stratification in advanced ovarian clear cell carcinoma.
     Gynecol Oncol. 2024;191:56-66.
     PubMed     Abstract available
     
     
     
340. LINDQUIST S, Kjaer SK, Frederiksen K, Ornskov D, et al
     Comparative analysis of HPV testing versus cytology in Danish cervical cancer screening: Insights from a large-scale implementation study.
     Gynecol Oncol. 2024;191:45-55.
     PubMed     Abstract available
     
     
     
341. PRAISS AM, Dagher C, Zhou Q, Iasonos A, et al
     Lymph node metastases in endometrial carcinoma: A modern assessment in the era of sentinel lymph node mapping and molecular subtyping.
     Gynecol Oncol. 2024;191:37-44.
     PubMed     Abstract available
     
     
     
342. YANG X, Li C, Li Z, Du D, et al
     The clinical value of ultrasound-guided sacral anesthesia in Intracavitary and/or interstitial brachytherapy for cervical Cancer.
     Gynecol Oncol. 2024;191:31-36.
     PubMed     Abstract available
     
     
     
343. LI X, Argenta PA, Brown K, Honeyfield K, et al
     Associations of cytomegalovirus infection with cancer-related cognitive impairment and peripheral neuropathy in ovarian cancer survivors.
     Gynecol Oncol. 2024;191:25-30.
     PubMed     Abstract available
     
     
     
344. JANG EB, Lee AJ, So KA, Lee SJ, et al
     Risk factors for the recurrence in patients with early endometrioid endometrial cancer achieving complete remission for fertility-sparing hormonal treatment.
     Gynecol Oncol. 2024;191:19-24.
     PubMed     Abstract available
     
     
     
345. ANASTASIO MK, Nolin A, Penvose KN, Lambert K, et al
     Adjuvant therapy and recurrence risk in non-myoinvasive high-grade (stage IC) endometrial cancer: A systematic review and meta-analysis.
     Gynecol Oncol. 2024;191:10-18.
     PubMed     Abstract available
     
     
     
346. NIEF CA, Long SE, McCleary TL, Kidd E, et al
     Diabetes mellitus complications associated with recurrence of stage I endometrioid endometrial cancer: A single-center retrospective study.
     Gynecol Oncol. 2024;190:298-306.
     PubMed     Abstract available
     
     
     
347. MOUFARRIJ S, Gazzo A, Rana S, Selenica P, et al
     Concurrent POLE hotspot mutations and mismatch repair deficiency/microsatellite instability in endometrial cancer: A challenge in molecular classification.
     Gynecol Oncol. 2024;191:1-9.
     PubMed     Abstract available
     
     
     
348. FULLERTON R, Martell K, Khanolkar R, Phan T, et al
     Impact of immune, inflammatory and nutritional indices on outcome in patients with locally advanced cervical cancer treated with definitive (chemo)radiotherapy.
     Gynecol Oncol. 2024;190:291-297.
     PubMed     Abstract available
     
     
     
349. BROWN J, Miller A, Holman LL, Backes F, et al
     Results of a randomized phase II trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent Chemonaive stromal ovarian tumors: An NRG oncology/gynecologic oncology group study14.
     Gynecol Oncol. 2024;190:283-290.
     PubMed     Abstract available
     
     
     
350. NAHSHON C, Leitao MM Jr, Segev Y
     Response to the letter to the editor: Referring to the manuscript entitled "Surgical nodal assessment for endometrial hyperplasia - A meta-analysis and systematic review".
     Gynecol Oncol. 2024;190:262-263.
     PubMed    
     
     
     
351. ADJEI NN, Haas A, Zhao H, Primm KM, et al
     Real-world trends in the use of maintenance therapy in ovarian cancer across the United States from 2017 to 2021.
     Gynecol Oncol. 2024;190:255-261.
     PubMed     Abstract available
     
     
     
352. NGUYEN L, Chung TH, Le YL, Reygaerts H, et al
     Hispanic individuals' cervical cancer screening disparities amidst the COVID-19 pandemic.
     Gynecol Oncol. 2024;190:243-249.
     PubMed     Abstract available
     
     
     
353. RIOS-DORIA E, Nobre SP, Sassine D, Glaser G, et al
     Impact of adjuvant therapy on oncologic outcomes in uterine-confined clear cell carcinoma of the endometrium.
     Gynecol Oncol. 2024;190:236-242.
     PubMed     Abstract available
     
     
     
354. MOKSHAGUNDAM S, McGree ME, Tapia AL, Fought AJ, et al
     Physical and psychological distress amongst patients undergoing neoadjuvant chemotherapy for advanced ovarian cancer.
     Gynecol Oncol. 2024;190:230-235.
     PubMed     Abstract available
     
     
     
355. YOUNG AN, Lin LH, Abel MK, Badhey MO, et al
     Atypical placental site nodules: Clinicopathologic features, management and patient outcomes in an institutional series.
     Gynecol Oncol. 2024;190:215-221.
     PubMed     Abstract available
     
     
     
356. POTHURI B, Sawaged Z, Karpel HC, Li X, et al
     A phase 2 feasibility study of nab-paclitaxel and carboplatin in epithelial carcinoma of the uterus.
     Gynecol Oncol. 2024;190:209-214.
     PubMed     Abstract available
     
     
     
357. PIFER PM, Kilar CR, Beriwal S
     Is substantial lymphovascular space invasion in FIGO stage I endometrial carcinoma ready for primetime in deciding adjuvant treatment?
     Gynecol Oncol. 2024;188:A1-A3.
     PubMed    
     
     
     
358. WALL JA, Pozzar RA, Enzinger AC, Tavormina A, et al
     Improving the palliative-procedure decision-making process for patients with peritoneal carcinomatosis: A secondary analysis.
     Gynecol Oncol. 2024;188:125-130.
     PubMed     Abstract available
     
     
     
359. WILKE RN, Iniesta MD, Fellman B, Jazaeri AA, et al
     A colostomy for large bowel obstruction at the end of life: What do patients gain from palliative surgery?
     Gynecol Oncol. 2024;188:120-124.
     PubMed     Abstract available
     
     
     
360. MONK BJ, Tewari KS, Randall LM, Pothuri B, et al
     Immunotherapy in locally advanced cervix cancer: A critical appraisal of the FDA indication based on ENGOT-CX11/GOG-3047/KEYNOTE-A18.
     Gynecol Oncol. 2024;188:81-82.
     PubMed    
     
     
     
361. LAMBERT KA, Albright BB, Anastasio MK, Kaplan SJ, et al
     Scalp hypothermia to reduce chemotherapy-induced alopecia: A systematic review and meta-analysis.
     Gynecol Oncol. 2024;188:71-80.
     PubMed     Abstract available
     
     
     
362. WILHITE AM, Wu S, Xiu J, Gibney GT, et al
     A paradigm shift in understanding vulvovaginal melanoma as a distinct tumor type compared with cutaneous melanoma.
     Gynecol Oncol. 2024;188:13-21.
     PubMed     Abstract available
     
     
     
363. POZZAR RA, Enzinger AC, Howard C, Tavormina A, et al
     Feasibility and acceptability of a nurse-led telehealth intervention (BOLSTER) to support patients with peritoneal carcinomatosis and their caregivers: A pilot randomized clinical trial.
     Gynecol Oncol. 2024;188:1-7.
     PubMed     Abstract available
     
     
     August 2024
364. LIM H, Kim SI, Kim MK, Yoon SH, et al
     Initial sarcopenia and body composition changes as prognostic factors in cervical cancer patients treated with concurrent chemoradiation: An artificial intelligence-based volumetric study.
     Gynecol Oncol. 2024;190:200-208.
     PubMed     Abstract available
     
     
     
365. MILLER EA, Chowdhary B, Chapman-Davis E
     Beyond the decision: Reproductive justice and cervical cancer care in a post-Dobbs era.
     Gynecol Oncol. 2024;190:186-188.
     PubMed     Abstract available
     
     
     
366. MEERNIK C, Osazuwa-Peters OL, Wilson LE, Joshi A, et al
     Frailty in patients with ovarian cancer and the role of healthcare access, race, and ethnicity.
     Gynecol Oncol. 2024;190:146-152.
     PubMed     Abstract available
     
     
     
367. FRICOVA L, Kommoss S, Scambia G, Ferron G, et al
     Reproductive outcomes after fertility-sparing surgery for cervical cancer - results of the multicenter FERTISS study.
     Gynecol Oncol. 2024;190:179-185.
     PubMed     Abstract available
     
     
     
368. QI C, Lyu M, Yao Z, Zhang F, et al
     SVIL promotes ovarian cancer progression and epithelial-mesenchymal transition under hypoxic conditions through the TGF-beta/Smad pathway.
     Gynecol Oncol. 2024;190:167-178.
     PubMed     Abstract available
     
     
     
369. CHUK E, Conway JL, Hanuschak J, Han K, et al
     Patient-reported sexual health outcomes of cervical cancer patients treated with definitive chemoradiation and MRI-guided brachytherapy.
     Gynecol Oncol. 2024;190:153-159.
     PubMed     Abstract available
     
     
     
370. KATO MK, Fujii E, Yamaguchi M, Higuchi D, et al
     Excellent concordance of the molecular classification between preoperative biopsy and final hysterectomy in endometrial carcinoma.
     Gynecol Oncol. 2024;190:139-145.
     PubMed     Abstract available
     
     
     
371. BARAKZAI SK, Bregar AJ, Del Carmen MG, Eisenhauer EL, et al
     The association of maintenance hormone therapy with overall survival in advanced-stage low-grade serous ovarian carcinoma: A risk-set matched retrospective study.
     Gynecol Oncol. 2024;190:119-123.
     PubMed     Abstract available
     
     
     
372. YUNOKAWA M, Kurihara N, Ishizuka N, Kanao H, et al
     Investigating the timing and site of recurrence for ovarian clear cell carcinoma: Analysis of the JGOG/GCIG trial-JGOG 3017-A3.
     Gynecol Oncol. 2024;190:113-118.
     PubMed     Abstract available
     
     
     
373. SKOF E, Stegel V, Dragos VS, Blatnik A, et al
     Exploring the impact of BRCA1 and BRCA2 mutation type and location on Olaparib maintenance therapy in platinum-sensitive relapsed ovarian Cancer patients: A single center report.
     Gynecol Oncol. 2024;190:104-112.
     PubMed     Abstract available
     
     
     
374. LEMIEUX M, Telles R, Goodheart M, Dahmoush L, et al
     Quality of life and survivorship in patients with low-grade ovarian cancer.
     Gynecol Oncol. 2024;190:96-103.
     PubMed     Abstract available
     
     
     
375. KOTSOPOULOS J, Lubinski J, Huzarski T, Bychkovsky BL, et al
     Incidence of endometrial cancer in BRCA mutation carriers.
     Gynecol Oncol. 2024;189:148-155.
     PubMed     Abstract available
     
     
     
376. WAGAR MK, Patel UJ, Bharucha K, Heisler CA, et al
     Postoperative urinary retention by void trial methodology following radical hysterectomy for cervical cancer.
     Gynecol Oncol. 2024;190:90-95.
     PubMed     Abstract available
     
     
     
377. GUERRA RA, Kaplan C, Borno H, Boscardin J, et al
     The role of race/ethnicity and age in clinical trial knowledge among patients with gynecologic malignancy.
     Gynecol Oncol. 2024;190:84-89.
     PubMed     Abstract available
     
     
     
378. SUZUKI Y, Chen L, Matsuo K, Ferris JS, et al
     Weight-loss therapy in patients with obesity with endometrial intraepithelial neoplasia and uterine cancer.
     Gynecol Oncol. 2024;190:78-83.
     PubMed     Abstract available
     
     
     
379. GAMBLE CR, Huang Y, Quinn J, Melamed A, et al
     Neighborhood economic vulnerability as a predictor for patterns of care and outcomes for patients with uterine cancer.
     Gynecol Oncol. 2024;190:70-77.
     PubMed     Abstract available
     
     
     
380. ROSS TL, Na R, Au-Yeung G, DeFazio A, et al
     Are exercise and sitting time during chemotherapy for ovarian cancer associated with treatment-related side-effects, chemotherapy completion and survival?
     Gynecol Oncol. 2024;190:53-61.
     PubMed     Abstract available
     
     
     
381. YOKOI A, Machida H, Shimada M, Mastuo K, et al
     Efficacy and safety of minimally invasive surgery versus open laparotomy for epithelial ovarian cancer: A systematic review and meta-analysis.
     Gynecol Oncol. 2024;190:42-52.
     PubMed     Abstract available
     
     
     
382. GU Y, Liu Y, Cheng H, Wang W, et al
     Clinicopathological characteristics and oncologic outcomes of patients with gestational trophoblastic neoplasia manifesting as isolated pulmonary lesions.
     Gynecol Oncol. 2024;190:28-34.
     PubMed     Abstract available
     
     
     
383. CUN HT, Bernard L, Lande KT, Lawson BC, et al
     Comprehensive molecular characterization of early stage grade 3 endometrioid endometrial adenocarcinoma.
     Gynecol Oncol. 2024;189:138-145.
     PubMed     Abstract available
     
     
     
384. FROEDING LP, Jensen PT
     Commentary on "Simple versus radical hysterectomy in women with low-risk cervical cancer" by Plante M. et al. published in The New England Journal of Medicine.
     Gynecol Oncol. 2024;189:137.
     PubMed    
     
     
     
385. OSTBY SA, Narasimhulu D, Ochs Kinney MA, Cliby W, et al
     Defining optimal perioperative analgesia in patients undergoing laparotomy for advanced gynecologic malignancy: A randomized controlled trial.
     Gynecol Oncol. 2024;190:11-17.
     PubMed     Abstract available
     
     
     
386. RIEDINGER CJ, Sakach J, Maples JM, Fulton J, et al
     Glucagon-like peptide-1 (GLP-1) receptor agonists for weight management: A review for the gynecologic oncologist.
     Gynecol Oncol. 2024;190:1-10.
     PubMed     Abstract available
     
     
     
387. HOLTZMAN S, Gellman C, Kaplowitz E, Barber E, et al
     Yes, it's true: Benign hysterectomy trends for gynecologic oncologists in the United States from 2015 to 2021.
     Gynecol Oncol. 2024;189:125-128.
     PubMed     Abstract available
     
     
     
388. CHELSEA NN, Posever N, Hsieh TYJ, Patterson S, et al
     Implementation of a financial navigation program in gynecologic oncology.
     Gynecol Oncol. 2024;189:119-124.
     PubMed     Abstract available
     
     
     
389. VAN DER EERDEN B, de Rooij BH, Schouten LJ, Boll D, et al
     Quality of life among borderline ovarian tumor survivors: A comparison with survivors of early-stage ovarian cancer and a cancer-free population: A cross-sectional population-based PROFILES study.
     Gynecol Oncol. 2024;189:111-118.
     PubMed     Abstract available
     
     
     
390. GLASER S, Han E
     Optimizing and harmonizing lymph node dissection and radiotherapy in advanced vulvar cancer.
     Gynecol Oncol. 2024;187:A1-A2.
     PubMed    
     
     
     
391. STROOT IAS, Bart J, Hollema H, Jalving M, et al
     Long-term outcome of high-grade serous carcinoma established in risk-reducing salpingo-oophorectomy specimens in asymptomatic BRCA1/2 germline pathogenic variant carriers.
     Gynecol Oncol. 2024;187:198-203.
     PubMed     Abstract available
     
     
     
392. WAGAR MK, Naik A, Zhang RC, Godecker A, et al
     Incidence of postoperative venous thromboembolism in patients with vulvar carcinoma undergoing vulvectomy with or without lymphadenectomy.
     Gynecol Oncol. 2024;187:192-197.
     PubMed     Abstract available
     
     
     
393. DEL VALLE D, Ruiz R, Lekuona A, Cobas P, et al
     Superparamagnetic iron oxide (SPIO) for sentinel lymph node detection in vulvar cancer.
     Gynecol Oncol. 2024;187:145-150.
     PubMed     Abstract available
     
     
     
394. VAN DEN BERG CB, Dasgupta S, Ewing-Graham PC, Bart J, et al
     Does serous tubal intraepithelial carcinoma (STIC) metastasize? The clonal relationship between STIC and subsequent high-grade serous carcinoma in BRCA1/2 mutation carriers several years after risk-reducing salpingo-oophorectomy.
     Gynecol Oncol. 2024;187:113-119.
     PubMed     Abstract available
     
     
     
395. ADOLPH L, Mann A, Liu XQ, Roberts L, et al
     Follow-up of women with cervical adenocarcinoma in situ treated by conization: A single centre clinical experience.
     Gynecol Oncol. 2024;187:74-79.
     PubMed     Abstract available
     
     
     
396. VUE NC, Sassani J, Prairie B, Yin Y, et al
     Clinical outcomes with utilization of high-potency topical steroids in patients with lichen sclerosus-associated vulvar cancer.
     Gynecol Oncol. 2024;187:58-63.
     PubMed     Abstract available
     
     
     
397. SWIFT BE, Khoja L, Matthews J, Croke J, et al
     Management of inguinal lymph nodes in locally advanced, surgically unresectable, squamous cell carcinoma of the vulva.
     Gynecol Oncol. 2024;187:46-50.
     PubMed     Abstract available
     
     
     July 2024
398. DA COSTA AABA, Souza RP, Pandolfi NC, de Souza Castro F, et al
     Should we consider progression-free survival benefits enough for drug approvals in locally advanced cervical cancer?
     Gynecol Oncol. 2024;189:109-110.
     PubMed    
     
     
     
399. JOHANSEN G, Lampic C, Floter Radestad A, Dahm-Kahler P, et al
     Health-related quality of life, sexual function, psychological health, reproductive concerns and fertility outcome in young women treated with fertility-sparing surgery for ovarian tumors - A prospective longitudinal multicentre study.
     Gynecol Oncol. 2024;189:101-108.
     PubMed     Abstract available
     
     
     
400. ZANNONI GF, Santoro A, Arciuolo D, Travaglino A, et al
     Endometrial cancer and 2023 FIGO staging system: Not too soon, but maybe too much?
     Gynecol Oncol. 2024;189:98-100.
     PubMed    
     
     
     
401. GUPTA A, O'Cearbhaill RE, Block MS, Hamilton E, et al
     Vaccination with folate receptor-alpha peptides in patients with ovarian cancer following response to platinum-based therapy: A randomized, multicenter clinical trial.
     Gynecol Oncol. 2024;189:90-97.
     PubMed     Abstract available
     
     
     
402. SULLIVAN MW, Kanbergs AN, Growdon WB
     Letter to the Editor: Referring to the manuscript entitled "Surgical nodal assessment for endometrial hyperplasia - A meta-analysis and systematic review" recently reported from Nahshon et al. (Gynecol Oncol., 188;140-146;2024).
     Gynecol Oncol. 2024;189:88-89.
     PubMed    
     
     
     
403. HUEPENBECKER SP, Soliman PT, Meyer LA, Iniesta MD, et al
     Perioperative outcomes in gynecologic pelvic exenteration before and after implementation of an enhanced recovery after surgery program.
     Gynecol Oncol. 2024;189:80-87.
     PubMed     Abstract available
     
     
     
404. FINCH L, Broach V, Feinberg J, Al-Niaimi A, et al
     ChatGPT compared to national guidelines for management of ovarian cancer: Did ChatGPT get it right? - A Memorial Sloan Kettering Cancer Center Team Ovary study.
     Gynecol Oncol. 2024;189:75-79.
     PubMed     Abstract available
     
     
     
405. LEE YW, Wang V, Wang MJ, Kim KH, et al
     The effects of Asian American Pacific Islander (AAPI) data inequities in gynecologic oncology.
     Gynecol Oncol. 2024;189:64-67.
     PubMed     Abstract available
     
     
     
406. KAMRAVA MR, Gonzalez-Martin A, Pothuri B, Vergote I, et al
     Patterns of initial ovarian cancer recurrence on niraparib maintenance monotherapy in patients with no baseline evidence of disease after first-line chemotherapy: An ad hoc subgroup analysis of PRIMA/ENGOT-OV26/GOG-3012.
     Gynecol Oncol. 2024;189:68-74.
     PubMed     Abstract available
     
     
     
407. CABRERA S, Bebia V, Lopez-Gil C, Luzarraga-Aznar A, et al
     Molecular classification improves preoperative risk assessment of endometrial cancer.
     Gynecol Oncol. 2024;189:56-63.
     PubMed     Abstract available
     
     
     
408. BERGSTEIN A, Huang Y, Hershman DL, Xu X, et al
     Impact of medicaid expansion on cervical cancer screening: A state-specific difference in difference analysis.
     Gynecol Oncol. 2024;189:49-55.
     PubMed     Abstract available
     
     
     
409. SENGUTTUVAN RN, Lugo-Santiago N, Nakamura B, Song M, et al
     Uterine cancer restaging according to the updated 2023 FIGO Guidelines does not uniformly affect prognosis: An institutional retrospective cohort study.
     Gynecol Oncol. 2024;189:41-48.
     PubMed     Abstract available
     
     
     
410. POLAN RM, Ali-Fehmi R, Grace AK, Mattei LH, et al
     Occult residual ovarian tissue at the time of minimally invasive risk reducing surgery in women with BRCA mutations.
     Gynecol Oncol. 2024;189:37-40.
     PubMed     Abstract available
     
     
     
411. ANDRES S, Finch L, Iasonos A, Zhou Q, et al
     Basket study of oral progesterone antagonist onapristone extended release in progesterone receptor-positive recurrent granulosa cell, low-grade serous ovarian cancer, or endometrioid endometrial cancer.
     Gynecol Oncol. 2024;189:30-36.
     PubMed     Abstract available
     
     
     
412. MAHONEY DE, Mukherjee R, Thompson J
     Elucidating the influences of social determinants of health on perceived overall health among African American/Black and Hispanic ovarian cancer survivors using the NIH All of Us Research Program.
     Gynecol Oncol. 2024;189:24-29.
     PubMed     Abstract available
     
     
     
413. MCNAMARA B, Greenman M, Bellone S, Santin LA, et al
     Preclinical activity of datopotamab deruxtecan, a novel TROP2 directed antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2) in ovarian carcinoma.
     Gynecol Oncol. 2024;189:16-23.
     PubMed     Abstract available
     
     
     
414. ARO K, Pasanen A, Butzow R, Loukovaara M, et al
     The impact of estrogen receptor and L1 cell adhesion molecule expression on endometrial cancer outcome correlates with clinicopathological risk group and molecular subgroup.
     Gynecol Oncol. 2024;189:9-15.
     PubMed     Abstract available
     
     
     
415. GRAHAM O, Rodriguez J, Abbott R, Lomonosova E, et al
     A toolkit for a modern gynecologic oncology tissue bank.
     Gynecol Oncol. 2024;189:1-8.
     PubMed     Abstract available
     
     
     
416. EZENDAM NPM, de Rooij BH, Creutzberg CL, Kruitwagen RFPM, et al
     Effect of reduced follow-up care on patient satisfaction with care among patients with endometrial cancer: The ENSURE randomized controlled trial.
     Gynecol Oncol. 2024;188:169-183.
     PubMed     Abstract available
     
     
     
417. KUMAR PP, Smith D, Key J, Dong H, et al
     Preclinical 3D model screening reveals digoxin as an effective therapy for a rare and aggressive type of endometrial cancer.
     Gynecol Oncol. 2024;188:162-168.
     PubMed     Abstract available
     
     
     
418. SHALOWITZ DI, Rajczi A
     Refining research on access to gynecologic cancer care: The DIMeS framework.
     Gynecol Oncol. 2024;188:158-161.
     PubMed     Abstract available
     
     
     
419. CROWLEY F, Broderick S, Francis JH, O'Cearbhaill RE, et al
     Ocular side effects of anticancer agents used in the treatment of gynecologic cancers.
     Gynecol Oncol. 2024;188:147-157.
     PubMed     Abstract available
     
     
     
420. NAHSHON C, Leitao MM Jr, Lavie O, Schmidt M, et al
     Surgical nodal assessment for endometrial hyperplasia - A meta-analysis and systematic review.
     Gynecol Oncol. 2024;188:140-146.
     PubMed     Abstract available
     
     
     
421. STEWART KT, Jafari H, Pattillo J, Santos J, et al
     Avoiding the needle: A quality improvement program introducing apixaban for extended thromboprophylaxis after major gynecologic cancer surgery.
     Gynecol Oncol. 2024;188:131-139.
     PubMed     Abstract available
     
     
     
422. RODRIGUEZ GC, Yozwiak M, Nelson OL, Zhang HH, et al
     The karyometric signature is altered in fallopian tubes with serous tubal intraepithelial carcinoma.
     Gynecol Oncol. 2024;186:110-116.
     PubMed     Abstract available
     
     
     June 2024
423. FUMAGALLI D, Sonik R, De Vitis LA, Rossi V, et al
     Evaluating nutrition in advanced ovarian cancer: which biomarker works best?
     Gynecol Oncol. 2024;188:97-102.
     PubMed     Abstract available
     
     
     
424. MEADE CE, Sinnott JA, Backes FJ, Cosgrove CM, et al
     Associations between race and ethnicity and treatment setting among gynecologic cancer patients.
     Gynecol Oncol. 2024;188:111-119.
     PubMed     Abstract available
     
     
     
425. MIRZA MR, Tandaric L, Henriksen JR, Maenpaa J, et al
     NSGO-OV-UMB1/ENGOT-OV30: A phase II study of durvalumab in combination with the anti-CD73 monoclonal antibody Oleclumab in patients with relapsed ovarian cancer.
     Gynecol Oncol. 2024;188:103-110.
     PubMed     Abstract available
     
     
     
426. KA K, Cordoba A, Cagetti LV, Schiappa R, et al
     Preoperative brachytherapy of early-stage cervical cancer: A multicenter study by the SFRO brachytherapy group.
     Gynecol Oncol. 2024;188:90-96.
     PubMed     Abstract available
     
     
     
427. KOCIAN R, Kohler C, Bajsova S, Jarkovsky J, et al
     Sentinel lymph node pathological ultrastaging: Final outcome of the Sentix prospective international study in patients with early-stage cervical cancer.
     Gynecol Oncol. 2024;188:83-89.
     PubMed     Abstract available
     
     
     
428. MANNING-GEIST BL, Sullivan MW, Zhou Q, Iasonos A, et al
     Folate receptor alpha expression in low-grade serous ovarian cancer: Exploring new therapeutic possibilities.
     Gynecol Oncol. 2024;188:52-57.
     PubMed     Abstract available
     
     
     
429. KOH B, Ryu JY, Noh JJ, Hwang JR, et al
     Anti-cancer effects of benzimidazole derivative BNZ-111 on paclitaxel-resistant ovarian cancer.
     Gynecol Oncol. 2024;188:60-70.
     PubMed     Abstract available
     
     
     
430. EKMANN-GADE AW, Hogdall CK, Seibaek L, Noer MC, et al
     Corrigendum to "Incidence, treatment, and survival trends in older versus younger women with epithelial ovarian cancer from 2005 to 2018: A nationwide Danish study" [Gynecologic Oncology 164/1(2022) 120-128].
     Gynecol Oncol. 2024;188:58-59.
     PubMed    
     
     
     
431. BHATNAGAR AR, Ghanem AI, Alkamachi B, Allo G, et al
     The prognostic impact of substantial lymphovascular space invasion in women with node negative FIGO stage I uterine carcinoma.
     Gynecol Oncol. 2024;188:44-51.
     PubMed     Abstract available
     
     
     
432. GARZON S, Calio A, Ferrari FA, Iannicello CQ, et al
     Uterine perivascular epithelioid cell tumors (PEComa) and the accuracy of proposed classification systems in predicting the malignant versus non-malignant behavior.
     Gynecol Oncol. 2024;188:35-43.
     PubMed     Abstract available
     
     
     
433. CHEN H, Chen Y, Zheng A, Tan X, et al
     Is pharmacologic venous Thromboprophylaxis necessary for patients undergoing minimally invasive surgery for endometrial Cancer? A systematic review and Meta-analysis.
     Gynecol Oncol. 2024;188:27-34.
     PubMed     Abstract available
     
     
     
434. WALKER CA, Edwards C, McIntire D, Makepeace L, et al
     Predicting VTE and utility of thromboprophylaxis in metastatic and recurrent cervical cancer.
     Gynecol Oncol. 2024;188:22-26.
     PubMed     Abstract available
     
     
     
435. PATEL KB, Escamilla V, Wolfe L, Morris T, et al
     Food deserts, endometrial cancer survivors, and healthy food access: Is it equitable in rural America? - A geospatial analysis.
     Gynecol Oncol. 2024;188:8-12.
     PubMed     Abstract available
     
     
     
436. FLANIGAN MR, Bell SG, Donovan HS, Zhao J, et al
     Variables impacting prolonged post-anesthesia care unit length of stay in gynecologic cancer patients in the era of same day minimally invasive hysterectomy.
     Gynecol Oncol. 2024;186:211-215.
     PubMed     Abstract available
     
     
     
437. BORHO L, Bao R, Elishaev E, Dinkins KD, et al
     Association of allostatic load with overall survival in epithelial ovarian cancer.
     Gynecol Oncol. 2024;186:204-210.
     PubMed     Abstract available
     
     
     
438. CHAN JK, Tewari K, Monk BJ, Herzog TJ, et al
     Biomarker guidance in selection among breakthrough treatment options in advanced and recurrent endometrial cancer.
     Gynecol Oncol. 2024;187:249-252.
     PubMed    
     
     
     
439. MAKKER V, Perez-Fidalgo JA, Valabrega G, Hamilton E, et al
     Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study.
     Gynecol Oncol. 2024 Jun 3:S0090-8258(24)00234.
     PubMed     Abstract available
     
     
     
440. AISAGBONHI O, Ghlichloo I, Hong DS, Roma A, et al
     Comprehensive next-generation sequencing identifies novel putative pathogenic or likely pathogenic germline variants in patients with concurrent tubo-ovarian and endometrial serous and endometrioid carcinomas or precursors.
     Gynecol Oncol. 2024;187:241-248.
     PubMed     Abstract available
     
     
     
441. VALABREGA G, Pothuri B, Oaknin A, Graybill WS, et al
     Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial.
     Gynecol Oncol. 2024;187:128-138.
     PubMed     Abstract available
     
     
     
442. O'CONNOR RM, Huang DS, Rimel BJ, Kim KH, et al
     Unmet financial needs among patients crowdfunding to support gynecologic cancer care.
     Gynecol Oncol. 2024;186:199-203.
     PubMed     Abstract available
     
     
     
443. BERTON D, Pautier P, Lorusso D, Gennigens C, et al
     Antitumor activity and safety of the PD-1 inhibitor retifanlimab in patients with recurrent microsatellite instability-high or deficient mismatch repair endometrial cancer: Final safety and efficacy results from cohort H of the POD1UM-101 phase I stud
     Gynecol Oncol. 2024;186:191-198.
     PubMed     Abstract available
     
     
     
444. CHALIF J, Kistenfeger Q, Fulton J, Morton M, et al
     Diagnosis and management of gastric-type endocervical adenocarcinoma: A case report and review of the literature.
     Gynecol Oncol. 2024;185:165-172.
     PubMed     Abstract available
     
     
     
445. SCALISE CB, Kincaid K, Thigpen H, Moore J, et al
     A spatial proteomic study of platinum refractory HGSOC implicates dual AKT and WNT activity linked to an immunosuppressive tumor microenvironment.
     Gynecol Oncol. 2024;185:83-94.
     PubMed     Abstract available
     
     
     
446. FEINBERG J, Da Cruz Paula A, da Silva EM, Pareja F, et al
     Adenoid cystic carcinoma of the Bartholin's gland is underpinned by MYB- and MYBL1- rearrangements.
     Gynecol Oncol. 2024;185:58-67.
     PubMed     Abstract available
     
     
     
447. HOHN AK, Forberger M, Alfaraidi M, Gilks CB, et al
     High concordance of molecular subtyping between pre-surgical biopsy and surgical resection specimen (matched-pair analysis) in patients with vulvar squamous cell carcinoma using p16- and p53-immunostaining.
     Gynecol Oncol. 2024;185:17-24.
     PubMed     Abstract available
     
     
     May 2024
448. FRANCO S, Godley LA
     Myeloid neoplasms in individuals with breast and ovarian cancer and the association with deleterious germline variants.
     Gynecol Oncol. 2024;187:235-240.
     PubMed     Abstract available
     
     
     
449. LOF P, van Soolingen NJ, Piek JMJ, Aarts JWM, et al
     Preferences and considerations for interval cytoreductive surgery in advanced ovarian cancer: The patient's perspective.
     Gynecol Oncol. 2024;187:227-234.
     PubMed     Abstract available
     
     
     
450. PITIYARACHCHI O, Ansell PJ, Coleman RL, Dinh MH, et al
     Homologous recombination deficiency should be tested for in patients with advanced stage high-grade serous ovarian cancer aged 70 years and over.
     Gynecol Oncol. 2024;187:221-226.
     PubMed     Abstract available
     
     
     
451. YUAN G, Zhang K, Zheng H, Wu Y, et al
     Suvemcitug plus chemotherapy for platinum-resistant epithelial ovarian, fallopian tube and primary peritoneal cancer: A phase 1b dose-escalation trial.
     Gynecol Oncol. 2024;187:212-220.
     PubMed     Abstract available
     
     
     
452. CARBALLO EV, Kim KH, Penn CA
     Trends in estimated PARP inhibitor eligibility and benefit among US epithelial ovarian cancer patients.
     Gynecol Oncol. 2024;187:204-211.
     PubMed     Abstract available
     
     
     
453. OSAZUWA-PETERS OL, Greiner MA, Kaufman BG, Zambrano Guevara LM, et al
     ACO leakage among gynecologic cancer patients: Incidence, predictors, and impact on annual Medicare expenditure.
     Gynecol Oncol. 2024;187:184-191.
     PubMed     Abstract available
     
     
     
454. PERSSON J, Luhrs O, Geppert B, Ekdahl L, et al
     A prospective study evaluating an optimized sentinel node algorithm in early stage cervical cancer: The PROSACC-study.
     Gynecol Oncol. 2024;187:178-183.
     PubMed     Abstract available
     
     
     
455. MARCHETTI C, Ataseven B, Perrone AM, Cassani C, et al
     Clinical characteristics and survival outcome of early-stage, high-grade, serous tubo-ovarian carcinoma according to BRCA mutational status.
     Gynecol Oncol. 2024;187:170-177.
     PubMed     Abstract available
     
     
     
456. LARAJA A, Connor Y, Poulson MR
     The effect of urban racial residential segregation on ovarian cancer diagnosis, treatment, and survival.
     Gynecol Oncol. 2024;187:163-169.
     PubMed     Abstract available
     
     
     
457. FERRIS JS, Prest MT, Hur C, Chen L, et al
     Trends in uterine cancer incidence in the United States: The contribution of age, period and cohort effects.
     Gynecol Oncol. 2024;187:151-162.
     PubMed     Abstract available
     
     
     
458. ZENATRI M, Perennec T, Michon C, Gernier F, et al
     Pharmacogenomic predictor of long-term residual chemotherapy-induced peripheral neuropathy in ovarian cancer survivors: A substudy of the GINECO Vivrovaire study.
     Gynecol Oncol. 2024;187:139-144.
     PubMed     Abstract available
     
     
     
459. HUNSBERGER KS, Treiman S, Monk BJ, Tewari KS, et al
     A systematic review of stage IVA cervical cancer treatment: Challenges in the management of an understudied group.
     Gynecol Oncol. 2024;187:120-127.
     PubMed     Abstract available
     
     
     
460. LIU JF, Xiong N, Wenham RM, Wahner-Hendrickson A, et al
     A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparib.
     Gynecol Oncol. 2024;187:105-112.
     PubMed     Abstract available
     
     
     
461. ROSATI A, De Rose AM, Gallotta V, Giannarelli D, et al
     Feasibility and operative outcomes of surgery in the liver area in advanced ovarian cancer.
     Gynecol Oncol. 2024;187:98-104.
     PubMed     Abstract available
     
     
     
462. PIEDIMONTE S, Murray C, Atenafu EG, Rouzbahman M, et al
     Correlating the KELIM (CA125 elimination rate constant K) score and the chemo-response score as predictors of chemosensitivity in patients with advanced ovarian carcinoma.
     Gynecol Oncol. 2024;187:92-97.
     PubMed     Abstract available
     
     
     
463. KIM JH, Han KH, Park EY, Kim ET, et al
     Efficacy of immune-checkpoint inhibitors combined with cytotoxic chemotherapy in advanced or recurrent endometrial cancer: A systematic review and meta-analysis.
     Gynecol Oncol. 2024;187:85-91.
     PubMed     Abstract available
     
     
     
464. FILIPPOVA OT, Boecking K, Broach V, Gardner GJ, et al
     Trends in specific procedures performed at the time of cytoreduction for ovarian cancer: Is interval debulking surgery truly less radical? A Memorial Sloan Kettering Cancer Center Team Ovary study.
     Gynecol Oncol. 2024;187:80-84.
     PubMed     Abstract available
     
     
     
465. LIANG S, Ge H, Zhou S, Tang J, et al
     Prognostic factors of 87 ovarian yolk sac tumor (OYST) patients and molecular characteristics of persistent and recurrent OYST.
     Gynecol Oncol. 2024;187:64-73.
     PubMed     Abstract available
     
     
     
466. CHIBA Y, Kojima Y, Yazaki S, Yoshida H, et al
     Trop-2 expression and the tumor immune microenvironment in cervical cancer.
     Gynecol Oncol. 2024;187:51-57.
     PubMed     Abstract available
     
     
     
467. GONZALEZ-MARTIN A, Chung HC, Saada-Bouzid E, Yanez E, et al
     Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 study.
     Gynecol Oncol. 2024;186:182-190.
     PubMed     Abstract available
     
     
     
468. MATSUO K, Chen L, Klar M, Lee MW, et al
     Prognostic performance of the 2023 FIGO staging schema for endometrial cancer.
     Gynecol Oncol. 2024;187:37-45.
     PubMed     Abstract available
     
     
     
469. MITRIC C, Sayyid RK, Fleshner NE, Look Hong NJ, et al
     Hysterectomy versus chemotherapy for low-risk non-metastatic gestational trophoblastic neoplasia (GTN): A cost-effectiveness analysis.
     Gynecol Oncol. 2024;187:30-36.
     PubMed     Abstract available
     
     
     
470. PAPPAS TC, Roy Choudhury M, Chacko BK, Twiggs LB, et al
     Neural network-derived multivariate index assay demonstrates effective clinical performance in longitudinal monitoring of ovarian cancer risk.
     Gynecol Oncol. 2024;187:21-29.
     PubMed     Abstract available
     
     
     
471. DEMIRKIRAN C, Greenman M, Bellone S, McNamara B, et al
     Preclinical in vitro and in vivo activity of the RAF/MEK clamp avutometinib in combination with FAK inhibition in uterine carcinosarcomas.
     Gynecol Oncol. 2024;187:12-20.
     PubMed     Abstract available
     
     
     
472. RING KL, Duska LR
     How far is too far? Cancer prevention and clinical trial enrollment in geographically underserved patient populations.
     Gynecol Oncol. 2024;184:8-15.
     PubMed     Abstract available
     
     
     
473. MACCHIA G, Cilla S, Pezzulla D, Campitelli M, et al
     Efficacy of stereotactic body radiotherapy and response prediction using artificial intelligence in oligometastatic gynaecologic cancer.
     Gynecol Oncol. 2024;184:16-23.
     PubMed     Abstract available
     
     
     April 2024
474. HOLTZMAN S, McCarthy L, Estevez SL, Lee JA, et al
     Walking the tightrope: Fertility preservation among hereditary breast and ovarian Cancer syndrome Previvors.
     Gynecol Oncol. 2024;186:176-181.
     PubMed     Abstract available
     
     
     
475. JIANG Z, Zhu M, Zhang L, Cui H, et al
     Antitumor immunity and prognosis value elicited by FAT3 and LRP1B co-mutation in endometrial cancer.
     Gynecol Oncol. 2024;187:1-11.
     PubMed     Abstract available
     
     
     
476. HOFFMAN M, Dunsmore V, Cliby W, Chi D, et al
     Surgical training of gynecologic oncology fellows: Long-term trends and implications for future education.
     Gynecol Oncol. 2024;184:254-258.
     PubMed     Abstract available
     
     
     
477. SMITH AJB, O'Brien C, Haggerty A, Ko EM, et al
     "Having cancer is very expensive": A qualitative study of patients with ovarian cancer and PARP inhibitor treatment.
     Gynecol Oncol. 2024;186:170-175.
     PubMed     Abstract available
     
     
     
478. CHALIF J, Chambers LM, Yao M, Kuznicki M, et al
     Extended-duration antibiotics are not associated with a reduction in surgical site infection in patients with ovarian cancer undergoing cytoreductive surgery with large bowel resection.
     Gynecol Oncol. 2024;186:161-169.
     PubMed     Abstract available
     
     
     
479. PENG H, Jiang J, Li L, Hao Z, et al
     Mismatch repair deficiency and abnormal p53 expression has significant predictive value for progesterone resistance and endometrial tumorigenesis in patients with endometrial atypical hyperplasia receiving fertility-preserving treatment.
     Gynecol Oncol. 2024;186:154-160.
     PubMed     Abstract available
     
     
     
480. ALGERA MD, van Driel WJ, Slangen BFM, Wouters MWJM, et al
     Effect of surgical volume on short-term outcomes of cytoreductive surgery for advanced-stage ovarian cancer: A population-based study from the Dutch Gynecological Oncology Audit.
     Gynecol Oncol. 2024;186:144-153.
     PubMed     Abstract available
     
     
     
481. PATEL JM, Hermann CE, Growdon WB, Aviki E, et al
     ChatGPT accurately performs genetic counseling for gynecologic cancers.
     Gynecol Oncol. 2024;183:115-119.
     PubMed     Abstract available
     
     
     
482. WANG CC, Grubbs A, Foley OW, Bharadwa S, et al
     The activity advantage: Objective measurement of preoperative activity is associated with postoperative recovery and outcomes in patients undergoing surgery with gynecologic oncologists.
     Gynecol Oncol. 2024;186:137-143.
     PubMed     Abstract available
     
     
     
483. ZHAO Z, Wang J, Kong W, Fang Z, et al
     Intermittent energy restriction inhibits tumor growth and enhances paclitaxel response in a transgenic mouse model of endometrial cancer.
     Gynecol Oncol. 2024;186:126-136.
     PubMed     Abstract available
     
     
     
484. NELSON AT, Harris AK, Watson D, Kamihara J, et al
     Outcomes in ovarian Sertoli-Leydig cell tumor: A report from the International Pleuropulmonary Blastoma/DICER1 and Ovarian and Testicular Stromal Tumor Registries.
     Gynecol Oncol. 2024;186:117-125.
     PubMed     Abstract available
     
     
     
485. EHMANN S, Lam C, Zhou Q, Iasonos A, et al
     Secondary cytoreductive surgery and oncologic outcomes in the era of targeted maintenance therapy for recurrent, platinum-sensitive ovarian cancer.
     Gynecol Oncol. 2024;186:104-109.
     PubMed     Abstract available
     
     
     
486. ESPINOSA I, D'Angelo E, Prat J
     Endometrial carcinoma: 10 years of TCGA (the cancer genome atlas): A critical reappraisal with comments on FIGO 2023 staging.
     Gynecol Oncol. 2024;186:94-103.
     PubMed     Abstract available
     
     
     
487. MATSUO K, Huang Y, Matsuzaki S, Vallejo A, et al
     Cesarean hysterectomy for placenta accreta spectrum: Surgeon specialty-specific assessment.
     Gynecol Oncol. 2024;186:85-93.
     PubMed     Abstract available
     
     
     
488. GITTO SB, Ihewulezi CJN, Powell DJ Jr
     Adoptive T cell therapy for ovarian cancer.
     Gynecol Oncol. 2024;186:77-84.
     PubMed     Abstract available
     
     
     
489. DAHM-KAHLER P, Radestad AF, Holmberg E, Borgfeldt C, et al
     Has time to chemotherapy from primary debulking surgery in advanced ovarian cancer an impact on survival? - A population-based nationwide SweGCG study.
     Gynecol Oncol. 2024;186:69-76.
     PubMed     Abstract available
     
     
     
490. GIEN LT, Enserro DM, Block MS, Waggoner S, et al
     Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: An NRG oncology study GY016.
     Gynecol Oncol. 2024;186:61-68.
     PubMed     Abstract available
     
     
     
491. SAYLOR KW, Fernandes EQ, Adams M, Paraghamian S, et al
     Predictors of germline genetic testing referral and completion in ovarian cancer patients at a Comprehensive Cancer Center.
     Gynecol Oncol. 2024;186:53-60.
     PubMed     Abstract available
     
     
     
492. KOPELMAN ZA, Tian C, Tumas J, Phippen NT, et al
     Disease progression, survival, and molecular disparities in Black and White patients with endometrioid endometrial carcinoma in real-world registries and GOG/NRG oncology randomized phase III clinical trials.
     Gynecol Oncol. 2024;183:103-114.
     PubMed     Abstract available
     
     
     
493. HOLLIS RL, Elliott R, Dawson JC, Ilenkovan N, et al
     High throughput screening identifies dasatinib as synergistic with trametinib in low grade serous ovarian carcinoma.
     Gynecol Oncol. 2024;186:42-52.
     PubMed     Abstract available
     
     
     
494. VESZTERGOM D, Teglas G, Bahrehmand K, Torok A, et al
     Reducing radicality in fertility-sparing surgery is associated with improved in vitro fertilization outcome in early-stage cervical cancer: A national retrospective study.
     Gynecol Oncol. 2024;186:35-41.
     PubMed     Abstract available
     
     
     
495. 
     Introduction to SGO VSI.
     Gynecol Oncol. 2024;183:A7.
     PubMed    
     
     
     
496. RIEDINGER CJ, Barrington DA, Nagel CI, Khadraoui WK, et al
     Retraction notice to "Cost-effectiveness of chemotherapy and dostarlimab for advanced or recurrent endometrial cancer" [Gynecologic Oncology 183 (2024) 78-84].
     Gynecol Oncol. 2024;183:R1.
     PubMed    
     
     
     March 2024
497. MONTEMORANO L, Shultz ZB, Farooque A, Hyun M, et al
     TP53 mutations and the association with platinum resistance in high grade serous ovarian carcinoma.
     Gynecol Oncol. 2024;186:26-34.
     PubMed     Abstract available
     
     
     
498. SHEN X, Wang J, Deng B, Chen S, et al
     High-dose ascorbate exerts anti-tumor activities and improves inhibitory effect of carboplatin through the pro-oxidant function pathway in uterine serous carcinoma cell lines.
     Gynecol Oncol. 2024;183:93-102.
     PubMed     Abstract available
     
     
     
499. SALINARO JR, Rossi EC, Penvose KN, Zhang Y, et al
     Delayed publication of clinical trials in gynecologic oncology.
     Gynecol Oncol. 2024;183:74-77.
     PubMed     Abstract available
     
     
     
500. HUANG Y, Rauh-Hain JA, McCoy TH, Hou JY, et al
     Comparing survival of older ovarian cancer patients treated with neoadjuvant chemotherapy versus primary cytoreductive surgery: Reducing bias through machine learning.
     Gynecol Oncol. 2024;186:9-16.
     PubMed     Abstract available
     
     
     
501. DESRAVINES N, Hazimeh D, Desjardins MR, Wethington SL, et al
     Healthcare utilization in women diagnosed with endometrial cancer: A survey-based study.
     Gynecol Oncol. 2024;186:1-8.
     PubMed     Abstract available
     
     
     
502. WILLIAMS-BROWN MY, Summey RM, Newtson A, Burke W, et al
     System-level recommendations for improved wellness for gynecologic oncologists: A Society of Gynecologic Oncology Review.
     Gynecol Oncol. 2024;183:85-92.
     PubMed     Abstract available
     
     
     
503. RIEDINGER CJ, Barrington DA, Nagel CI, Khadraoui WK, et al
     Cost-effectiveness of chemotherapy and dostarlimab for advanced or recurrent endometrial cancer.
     Gynecol Oncol. 2024;183:78-84.
     PubMed     Abstract available
     
     
     
504. KIM NK, Choi CH, Seong SJ, Lee JM, et al
     Treatment outcomes according to various progestin treatment strategies in patients with atypical hyperplasia/endometrial intraepithelial neoplasia - Multicenter retrospective study (KGOG2033).
     Gynecol Oncol. 2024;183:68-73.
     PubMed     Abstract available
     
     
     
505. PASSARELLI A, Carbone V, Pignata S, Mazzeo R, et al
     Alpelisib for PIK3CA-mutated advanced gynecological cancers: First clues of clinical activity.
     Gynecol Oncol. 2024;183:61-67.
     PubMed     Abstract available
     
     
     
506. LIANG MI, Dholakia JD, Lee GM, Wang L, et al
     Dedicated financial hardship screening adds value to routine distress screening among gynecologic cancer patients.
     Gynecol Oncol. 2024;183:53-60.
     PubMed     Abstract available
     
     
     
507. AHSAN MD, Webster EM, Wolfe IA, McGonigle R, et al
     Personalized survivorship care: Routine breast cancer risk assessment in the gynecologic oncology clinic.
     Gynecol Oncol. 2024;183:47-52.
     PubMed     Abstract available
     
     
     
508. HARTMAN YAW, Kenkhuis MF, Stelten S, Brouwer CG, et al
     Demographic, clinical, and sociocognitive determinants related to physical activity and dietary intake in patients with ovarian cancer: A cross-sectional study.
     Gynecol Oncol. 2024;183:39-46.
     PubMed     Abstract available
     
     
     
509. LEVINE BJ
     Letter re: Ban et al., A personalized probabilistic approach to ovarian cancer diagnostics.
     Gynecol Oncol. 2024 Mar 15:S0090-8258(24)00155.
     PubMed    
     
     
     
510. ROSS DH, Gomez K, Harmon G, Mysz ML, et al
     Evaluating outcomes and toxicities for a newly implemented MRI-based brachytherapy program for cervical cancer.
     Gynecol Oncol. 2024;183:33-38.
     PubMed     Abstract available
     
     
     
511. CACCIOTTOLA L, Camboni A, Gatti E, Marbaix E, et al
     Fertility potential and safety assessment of residual ovarian cortex in young women diagnosed with epithelial borderline and early-stage malignant ovarian tumors.
     Gynecol Oncol. 2024;183:15-24.
     PubMed     Abstract available
     
     
     
512. BYRNE M, Sia TY, Fong C, Khurram A, et al
     Mainstreaming in parallel with ovarian cancer tumor testing to improve genetic testing uptake.
     Gynecol Oncol. 2024 Mar 14:S0090-8258(24)00144.
     PubMed     Abstract available
     
     
     
513. GASS P, Thiel FC, Haberle L, Ackermann S, et al
     Primary results of the AGO-Zervix-1 Study: A prospective, randomized phase III study to compare the effects of paclitaxel and topotecan with those of cisplatin and topotecan in the treatment of patients with recurrent and persistent cervical cancer.
     Gynecol Oncol. 2024;183:25-32.
     PubMed     Abstract available
     
     
     
514. BJERRE TRENT PK, Nordskar NJ, Wangen KR, Engeskaug MI, et al
     Corrigendum to "Self-reported lower extremity lymphedema and quality of life after surgical staging of endometrial carcinoma: A population based cross-sectional study" [Gynecologic Oncology 175 (2023) 72-80].
     Gynecol Oncol. 2024;183:7-8.
     PubMed    
     
     
     
515. GLASER GE, Maddy B, Kumar A, Ishitani K, et al
     Impact of pharmacogenomic profiles on post-surgical pain following laparotomy for gynecologic pathology.
     Gynecol Oncol. 2024;183:9-14.
     PubMed     Abstract available
     
     
     
516. PANDYA D, Tomita S, Rhenals MP, Swierczek S, et al
     Mutations in cancer-relevant genes are ubiquitous in histologically normal endometrial tissue.
     Gynecol Oncol. 2024;185:194-201.
     PubMed     Abstract available
     
     
     
517. GAFFNEY D, Matias-Guiu X, Mutch D, Scambia G, et al
     2023 FIGO staging system for endometrial cancer: The evolution of the revolution.
     Gynecol Oncol. 2024;184:245-253.
     PubMed     Abstract available
     
     
     
518. RICHARDSON DL, Moore KN, Vergote I, Gilbert L, et al
     Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRalpha)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer.
     Gynecol Oncol. 2024;185:186-193.
     PubMed     Abstract available
     
     
     
519. NOGUEIRA-RODRIGUES A, Giannecchini GV, Secord AA
     Real world challenges and disparities in the systemic treatment of ovarian cancer.
     Gynecol Oncol. 2024;185:180-185.
     PubMed     Abstract available
     
     
     
520. OLAWAIYE AB
     2023 FIGO staging for endometrial cancer, a look at both sides of the coin.
     Gynecol Oncol. 2024;184:243-244.
     PubMed    
     
     
     
521. EJAREDAR M, Ruzycki SM, Glazer TS, Trudeau P, et al
     Implementation of a surgical site infection prevention bundle in gynecologic oncology patients: An enhanced recovery after surgery initiative.
     Gynecol Oncol. 2024;185:173-179.
     PubMed     Abstract available
     
     
     
522. GLASER GE, Dowdy SC
     Sentinel lymph node biopsy in high-risk endometrial cancer: The denouement.
     Gynecol Oncol. 2024;182:A1-A2.
     PubMed    
     
     
     
523. CHEN W, Xie J, Gao C, Zhang C, et al
     Hypertension associated with niraparib in cancer patients: A pharmacovigilance analysis based on the FAERS database and meta-analysis of randomized controlled trials.
     Gynecol Oncol. 2024;182:108-114.
     PubMed     Abstract available
     
     
     February 2024
524. CAO B, Li Y, Liu Y, Chen X, et al
     A multi-center study to predict the risk of intraoperative hypothermia in gynecological surgery patients using preoperative variables.
     Gynecol Oncol. 2024;185:156-164.
     PubMed     Abstract available
     
     
     
525. CHEN Y, Yang J, Wan Y, Li Q, et al
     DEAR model in overweight endometrial cancer patients undergoing fertility-sparing treatment: A randomized controlled trial.
     Gynecol Oncol. 2024;185:148-155.
     PubMed     Abstract available
     
     
     
526. COSTALES AB, Crane EK, Chambers L, Yao M, et al
     Laparoscopic predictability of minimally invasive interval debulking in advanced ovarian cancer: The MIID-SOC trial.
     Gynecol Oncol. 2024;185:143-147.
     PubMed     Abstract available
     
     
     
527. SALMAN L, Covens A, Vicus D, Podolsky S, et al
     The role of surgeon specialty in management and survival of malignant ovarian germ cell tumors: A population-based study.
     Gynecol Oncol. 2024;185:138-142.
     PubMed     Abstract available
     
     
     
528. RONCOLATO F, King MT, O'Connell RL, Lee YC, et al
     Hidden in plain sight - Survival consequences of baseline symptom burden in women with recurrent ovarian cancer.
     Gynecol Oncol. 2024;185:128-137.
     PubMed     Abstract available
     
     
     
529. AGUSTI N, Kanbergs A, Nitecki R
     Potential of molecular classification to guide fertility-sparing management among young patients with endometrial cancer.
     Gynecol Oncol. 2024;185:121-127.
     PubMed     Abstract available
     
     
     
530. MCNAMARA B, Demirkiran C, Hartwich TMP, Bellone S, et al
     Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer.
     Gynecol Oncol. 2024 Feb 9:S0090-8258(24)00043.
     PubMed     Abstract available
     
     
     
531. APPLEBAUM AJ
     The importance of family-focused care in the setting of advanced gynecological cancers.
     Gynecol Oncol. 2024;181:A1-A2.
     PubMed    
     
     
     
532. PELTECU G
     Eugen Bogdan Aburel, a pioneer of fertility sparing surgery.
     Gynecol Oncol. 2024;181:40-45.
     PubMed     Abstract available
     
     
     
533. VASTA FM, Cormio G, Cassani C, Bergamini A, et al
     Reproductive outcomes after conservative treatment in early and advanced stage MOGCTs.
     Gynecol Oncol. 2024;181:28-32.
     PubMed     Abstract available
     
     
     
534. TAYLOR DD, Gercel-Taylor C, Parker LP
     Retraction notice to "Patient-derived tumor reactive antibodies as diagnostic markers for ovarian cancer" [Gynecologic Oncology 115 (2009) 112-120].
     Gynecol Oncol. 2024;181:186.
     PubMed    
     
     
     January 2024
535. FADER AN, Ko EM, Pollock BD, Blank SV, et al
     An SGO commentary: U.S. News and World Report gynecologic oncology procedural ratings-Do they reflect high-quality care?
     Gynecol Oncol. 2024 Jan 25:S0090-8258(24)00002.
     PubMed     Abstract available
     
     
     October 2023
536. KIM JH, Kim SI, Park EY, Ha HI, et al
     Impact of postoperative residual disease on survival in epithelial ovarian cancer with consideration of recent frontline treatment advances: A systematic review and meta-analysis.
     Gynecol Oncol. 2023;179:24-32.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Gynecology is free of charge.